# EDGAR Filing Document

**Accession Number:** 0000083246
**File Stem:** 0001104659-23-009113
**Filing Date:** 2023-2
**Character Count:** 204961
**Document Hash:** e48a4eee45e69a8bfc9312c3f4ab1a73
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-23-009113.hdr.sgml**: 20230201

**ACCESSION NUMBER**: 0001104659-23-009113

**CONFORMED SUBMISSION TYPE**: 424B2

**PUBLIC DOCUMENT COUNT**: 7

**FILED AS OF DATE**: 20230201

**DATE AS OF CHANGE**: 20230201

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** HSBC USA INC /MD/
- **CENTRAL INDEX KEY:** 0000083246
- **STANDARD INDUSTRIAL CLASSIFICATION:** NATIONAL COMMERCIAL BANKS [6021]
- **IRS NUMBER:** 132764867
- **STATE OF INCORPORATION:** MD
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 424B2
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-253385
- **FILM NUMBER:** 23575686

**BUSINESS ADDRESS:**
- **STREET 1:** 452 FIFTH AVE
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10018
- **BUSINESS PHONE:** 212-525-5000

**MAIL ADDRESS:**
- **STREET 1:** 452 FIFTH AVENUE
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10018

Filed Pursuant to Rule 424(b)(2)

Registration No. 333-253385

January 30, 2023

PRICING SUPPLEMENT

(To Prospectus dated February 23, 2021,

Prospectus Supplement dated February 23, 2021 and

ETF Underlying Supplement dated February 23, 2021)

![](tm234869d18_424b2img01.jpg)

Linked to the iShares<sup>®</sup> MSCI EAFE ETF

► Semi-annual Coupon payments at a rate of 3.625% (equivalent to 7.25% per annum), payable on each Coupon Payment Date

► Callable semi-annually at the principal amount plus the applicable Coupon on any Call Observation Date on or after July 28, 2023 if
the Official Closing Price of the Reference Asset is at or above the Call Threshold

► If the Notes are not called you will receive protection from the first 25.00% of any losses if the Reference Return is less than
 -25.00%, with 1.3333x exposure to each 1% decline beyond -25.00%, and in such a case, you will lose all or a portion of your
 principal amount

► A 1 year and 6 month term if not called

► All payments on the Notes are subject to the credit risk of HSBC USA Inc.

The Autocallable Yield Notes (each a "Note" and collectively the "Notes") offered hereunder will not be listed on any securities exchange or automated quotation system.

Neither the U.S. Securities and Exchange Commission (the "SEC") nor any state securities commission has approved or disapproved of the Notes or passed upon the accuracy or the adequacy of this document, the accompanying prospectus, prospectus supplement or ETF Underlying Supplement. Any representation to the contrary is a criminal offense.

We have appointed HSBC Securities (USA) Inc., an affiliate of ours, as the agent for the sale of the Notes. HSBC Securities (USA) Inc. will purchase the Notes from us for distribution to other registered broker-dealers or will offer the Notes directly to investors. In addition, HSBC Securities (USA) Inc. or another of its affiliates or agents may use this pricing supplement in market-making transactions in any Notes after their initial sale. Unless we or our agent inform you otherwise in the confirmation of sale, this pricing supplement is being used in a market-making transaction. See "Supplemental Plan of Distribution (Conflicts of Interest)" on page PS-14 of this document.

**Investment in the Notes involves certain risks. You should refer to "Risk Factors" beginning on page PS-7 of this document, page S-1 of the accompanying prospectus supplement and page S-1 of the accompanying ETF Underlying Supplement.**

The Estimated Initial Value of the Notes on the Trade Date is $993.50 per Note, which is less than the price to public. The market value of the Notes at any time will reflect many factors and cannot be predicted with accuracy. See "Estimated Initial Value" on page PS-3 and "Risk Factors" beginning on page PS-7 of this document for additional information.

---

| | | | |
|:---|:---|:---|:---|
|  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Price to Public | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Underwriting Discount<sup>1</sup> | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Proceeds to Issuer |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Per Note | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$1000.00 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$3.75 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$996.25 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$8325000.00 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$31218.75 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$8293781.25 |

---

<sup>1</sup>HSBC USA Inc. or one of our affiliates may pay varying underwriting discounts of up to 0.375% per $1,000 Principal Amount in connection with the distribution of the Notes to other registered broker-dealers. See "Supplemental Plan of Distribution (Conflicts of Interest)" on page PS-14 of this document.

The Notes:

Are Not FDIC Insured <u>Are Not Bank Guaranteed</u> <u>May Lose Value</u>

![](tm234869d18_424b2img02.jpg)

---

| | |
|:---|:---|
| HSBC USA Inc. | ![](tm234869d18_424b2img03.jpg) |
| Autocallable Yield Notes | ![](tm234869d18_424b2img03.jpg) |

---

This document relates to a single offering of Autocallable Yield Notes. The Notes will have the terms described in this document and the accompanying prospectus, prospectus supplement, and ETF Underlying Supplement. If the terms of the Notes offered hereby are inconsistent with those described in the accompanying prospectus, prospectus supplement, or ETF Underlying Supplement, the terms described in this document shall control.

This document relates to an offering of Notes linked to the Reference Asset. The purchaser of a Note will acquire a senior unsecured debt security of HSBC USA Inc. linked to the Reference Asset as described below. The following key terms relate to the offering of the Notes:

---

| | |
|:---|:---|
| **Issuer:** | HSBC USA Inc. |
| **Principal Amount:** | $1,000 per Note |
| **Reference Asset:** | The iShares<sup>®</sup> MSCI EAFE ETF (Ticker: EFA) |
| **Trade Date:** | January 30, 2023 |
| **Pricing Date:** | January 26, 2023 |
| **Original Issue Date:** | February 2, 2023 |
| **Final Valuation Date:** | July 30, 2024, subject to adjustment as described under "Additional Terms of the Notes―Valuation Dates" in the accompanying ETF Underlying Supplement. |
| **Maturity Date:** | August 2, 2024. The Maturity Date is subject to adjustment as described under "Additional Terms of the Notes―Coupon Payment Dates, Call Payment Dates and Maturity Date" in the accompanying ETF Underlying Supplement. |
| **Call Feature:** | If the Official Closing Price of the Reference Asset is at or above the Call Threshold on any Observation Date the Notes will be automatically called, and you will receive a cash payment, per $1,000 Principal Amount, equal to the Principal Amount plus the applicable Coupon on the corresponding Call Payment Date. |
| **Call Threshold:** | 100.00% of the Initial Value |
| **Payment at Maturity:** | Unless the Notes are called , on the Maturity Date, for each $1,000 Principal Amount, we will pay you the Final Settlement Value. |
| **Final Settlement Value:** | Unless the Notes are called , for each $1,000 Principal Amount, you will receive a cash payment on the Maturity Date, calculated as follows:<br>■ **If the Reference Return is greater than or equal to -25.00%**:<br>$1,000 + final Coupon.<br>■ **If the Reference Return of is less than -25.00%**:<br>$1,000 + [$1,000 × (Reference Return + 25.00%) × Downside Leverage Factor] + final Coupon.<br>If the Notes are not called and the Final Value is less than the Buffer Value, you will receive protection from the first 25.00% of any losses, with 1.3333x exposure to each 1% decline that the Reference Return is less than -25.00%. Under these circumstances will lose up to 100% of the Principal Amount. Even with the Coupons paid over the term of the Notes, your return on the Notes may be negative. |
| **Reference Return:**<br>| The quotient, expressed as a percentage, calculated as follows:<br><u>Final Value – Initial Value</u><br> Initial Value |

---

---

| | | | |
|:---|:---|:---|:---|
| **Observation Dates, Call Payment Dates and Coupon Payment Dates:** | **Observation Dates** | **Coupon Payment Dates** |  |
| **Observation Dates, Call Payment Dates and Coupon Payment Dates:** | July 28, 2023 \* | August 2, 2023 | \*\* |
| **Observation Dates, Call Payment Dates and Coupon Payment Dates:** | January 30, 2024 \* | February 2, 2024 | \*\* |
| **Observation Dates, Call Payment Dates and Coupon Payment Dates:** | July 30, 2024<br> (the Final Valuation Date)<br> \* | August 2, 2024<br> (the Maturity Date) | \*\* |

---

---

| | |
|:---|:---|
|  | \*These Observation Dates are also Call Observation Dates<br>\*\*These Coupon Payment Dates are also Call Payment Dates<br>Each subject to postponement as described under "Additional Terms of the Notes—Valuation Dates" and "Additional Terms of the Notes—Coupon Payment Dates, Call Payment Dates and Maturity Date" in the accompanying ETF Underlying Supplement. |
| **Call Observation Dates:** | The applicable Observation Dates on or after July 28, 2023, as indicated above. |
| **Call Payment Dates:** | The applicable Coupon Payment Dates on or after May 2, 2023, as indicated above. |
| **Coupon Rate:** | 3.625% per semi-annual period (equivalent to 7.25% per annum) |
| **Initial Value:** | $71.14, which was the Official Closing Price on the Pricing Date. |
| **Final Value:** | The Official Closing Price of the Reference Asset on the Final Valuation Date. |
| **Buffer Value:** | 75.00% of the Initial Value. |
| **Downside Leverage Factor:** | 1/0.75 (1.3333x) |
| **CUSIP/ISIN:** | 40441XF70 / US40441XF702 |
| **Form of Notes:** | Book-Entry |
| **Listing:** | The Notes will not be listed on any securities exchange or quotation system. |
| **Estimated Initial Value:** | The Estimated Initial Value of the Notes is less than the price you pay to purchase the Notes. The Estimated Initial Value does not represent a minimum price at which we or any of our affiliates would be willing to purchase your Notes in the secondary market, if any, at any time. See "Risk Factors — The Estimated Initial Value of the Notes, which was determined by us on the Trade Date, is less than the price to public and may differ from the market value of the Notes in the secondary market, if any." |

---

**GENERAL**

This document relates to an offering of Notes linked to the Reference Asset. The purchaser of a Note will acquire a senior unsecured debt security of HSBC USA Inc. Although the offering of Notes relates to the Reference Asset, you should not construe that fact as a recommendation as to the merits of acquiring an investment linked to the Reference Asset or any security included in the Reference Asset or as to the suitability of an investment in the Notes.

You should read this document together with the prospectus dated February 23, 2021, the prospectus supplement dated February 23, 2021 and the ETF Underlying Supplement dated February 23, 2021. If the terms of the Notes offered hereby are inconsistent with those described in the accompanying prospectus, prospectus supplement or ETF Underlying Supplement, the terms described in this document shall control. You should carefully consider, among other things, the matters set forth in "Risk Factors" beginning on page PS-7 of this document, page S-1 of the prospectus supplement and page S-1 of the ETF Underlying Supplement, as the Notes involve risks not associated with conventional debt securities. We urge you to consult your investment, legal, tax, accounting and other advisors before you invest in the Notes. As used herein, references to the "Issuer", "HSBC", "we", "us" and "our" are to HSBC USA Inc.

HSBC has filed a registration statement (including a prospectus, prospectus supplement and ETF Underlying Supplement) with the SEC for the offering to which this document relates. Before you invest, you should read the prospectus, prospectus supplement and ETF Underlying Supplement in that registration statement and other documents HSBC has filed with the SEC for more complete information about HSBC and this offering. You may get these documents for free by visiting EDGAR on the SEC's web site at www.sec.gov. Alternatively, HSBC Securities (USA) Inc. or any dealer participating in this offering will arrange to send you the prospectus, prospectus supplement and ETF Underlying Supplement if you request them by calling toll-free 1-866-811-8049.

You may also obtain:

🞂 The ETF Underlying Supplement at: [https://www.sec.gov/Archives/edgar/data/83246/000110465921026629/tm217170d6_424b2.htm](https://www.sec.gov/Archives/edgar/data/83246/000110465921026629/tm217170d6_424b2.htm)

🞂 The prospectus supplement at: [https://www.sec.gov/Archives/edgar/data/83246/000110465921026609/tm217170d2_424b2.htm](https://www.sec.gov/Archives/edgar/data/83246/000110465921026609/tm217170d2_424b2.htm)

🞂 The prospectus at: [https://www.sec.gov/Archives/edgar/data/83246/000110465921026585/tm217170d7_424b3.htm](https://www.sec.gov/Archives/edgar/data/83246/000110465921026585/tm217170d7_424b3.htm)

**PAYMENT ON THE NOTES**

**Call Feature**

If the Official Closing Price of the Reference Asset is at or above the Call Threshold on any Observation Date the Notes will be automatically called, and you will receive a cash payment, per $1,000 Principal Amount, equal to the Principal Amount plus the applicable Coupon on the corresponding Call Payment Date.

**Coupon**

Unless the Notes are called, we will pay a semi-annual Coupon payment on each Coupon Payment Date. For information regarding the record dates applicable to the Coupons payable on the Notes, please see the section entitled "Description of Notes—Interest and Principal Payments—Recipients of Interest Payments" beginning on page S-17 in the accompanying prospectus supplement. The Coupon Rate is 7.25% per annum (or $36.25 per $1,000 Principal Amount per semi-annual period).

**Payment at Maturity**

Unless the Notes are called , on the Maturity Date and for each $1,000 Principal Amount, you will receive a cash payment equal to the Final Settlement Value determined as follows:

■ **If the Reference Return is greater than or equal to -25.00%**:

$1,000 + final Coupon

■ **If the Reference Return is less than -25.00%**:

$1,000 + [$1,000 × (Reference Return + 25.00%) × Downside Leverage Factor] + final Coupon.

If the Notes are not called and the Final Value is less than the Buffer Value, you will receive protection from the first 25.00% of any losses, with 1.3333x exposure to each 1% decline of the Reference Return beyond -25.00%. Under these circumstances will lose up to 100% of the Principal Amount. Even with the Coupons paid over the term of the Notes, your return on the Notes may be negative.

**Calculation Agent**

We or one of our affiliates will act as calculation agent with respect to the Notes.

**Reference Sponsor**

The reference sponsor of the EFA is iShares, Inc.

**INVESTOR SUITABILITY**

**The Notes may be suitable for you if:**

🞂 You believe that the Final Value will be at or above the Buffer Value.

---

| | |
|:---|:---|
| 🞂 | You seek a fixed semi-annual Coupon, that will be paid at the Coupon Rate of 7.25% per annum to be paid on each Coupon Payment Date, unless the Notes are called. |

---

🞂 You are willing to invest in the Notes based on the fact that your maximum potential return is limited to the Coupons payable on the Notes.

🞂 You do not seek an investment that provides an opportunity to participate in the appreciation of the Reference Asset.

---

| | |
|:---|:---|
| 🞂 | You are willing to make an investment that is exposed to the potential downside performance of the Reference Asset if the Notes are not called on a 1.3333-to-1 basis for each percentage point that the Reference Return declines below -25.00%. |

---

---

| | |
|:---|:---|
| 🞂 | You are willing to lose up to 100% of the Principal Amount. |

---

---

| | |
|:---|:---|
| 🞂 | You are willing to hold the Notes which will be automatically called on any Observation Date on which the Official Closing Price of the Reference Asset is at or above the Call Threshold, or you are otherwise willing to hold the Notes to maturity. |

---

🞂 You are willing to forgo the dividends or other distributions paid on the stocks included in the Reference Asset.

🞂 You do not seek an investment for which there will be an active secondary market.

---

| | |
|:---|:---|
| 🞂 | You are willing to accept the risk and return profile of the Notes versus a conventional debt security with a comparable maturity issued by HSBC or another issuer with a similar credit rating. |

---

🞂 You are comfortable with the creditworthiness of HSBC, as Issuer of the Notes.

**The Notes may not be suitable for you if:**

🞂 You believe that the Final Value will be below the Buffer Value.

🞂 You believe that the Coupon will not provide you with your desired return.

🞂 You are unwilling to invest in the Notes based on the fact that your maximum potential return is limited to the Coupons payable on the Notes.

🞂 You seek an investment that provides an opportunity to participate in the appreciation of the Reference Asset.

---

| | |
|:---|:---|
| 🞂 | You are unwilling to make an investment that is exposed to the potential downside performance of the Reference Asset if the Notes are not called on a 1.3333-to-1 basis for each percentage point that the Reference Return declines below -25.00%. |

---

🞂 You seek an investment that provides full return of principal at maturity.

---

| | |
|:---|:---|
| 🞂 | You are unable or unwilling to hold Notes that will be automatically called on any Observation Date on which the Official Closing Price of the Reference Asset is at or above the Call Threshold, or you are otherwise unable or unwilling to hold the Notes to maturity. |

---

🞂 You prefer to receive the dividends or other distributions paid on the stocks included in the Reference Asset.

🞂 You seek an investment for which there will be an active secondary market.

---

| | |
|:---|:---|
| 🞂 | You prefer the lower risk, and therefore accept the potentially lower returns, of conventional debt securities with comparable maturities issued by HSBC or another issuer with a similar credit rating. |

---

🞂 You are not willing or are unable to assume the credit risk associated with HSBC, as Issuer of the Notes.

**RISK FACTORS**

We urge you to read the section "Risk Factors" beginning on page S-1 of the accompanying prospectus supplement and page S-1 of the accompanying ETF Underlying Supplement. You should understand the risks of investing in the Notes and should reach an investment decision only after careful consideration, with your advisors, of the suitability of the Notes in light of your particular financial circumstances and the information set forth in this document and the accompanying prospectus, prospectus supplement and ETF Underlying Supplement. In addition to the risks discussed below, you should review "Risk Factors" in the accompanying prospectus supplement and ETF Underlying Supplement including the explanation of risks relating to the Notes described in the following sections:

🞂 "—Risks Relating to All Note Issuances" in the prospectus supplement;

🞂 "—General Risks Related to Indices" in the ETF Underlying Supplement;

---

| | |
|:---|:---|
| 🞂 | "—Securities Prices Generally Are Subject to Political, Economic, Financial, and Social Factors that Apply to the Markets in which They Trade and, to a Lesser Extent, Foreign Markets" in the ETF Underlying Supplement; and |

---

🞂 "— Time Differences Between the Domestic and Foreign Markets and New York City May Create Discrepancies in the Trading Level or Price of the Notes" in the ETF Underlying Supplement.

You will be subject to significant risks not associated with conventional fixed-rate or floating-rate debt securities.

***Risks Relating to the Structure or Features of the Notes***

**The Notes do not guarantee any return of principal and you may lose all of your Principal Amount.**

The Notes do not guarantee any return of principal. The Notes differ from ordinary debt securities in that we will not pay you 100% of the Principal Amount of your Notes if the Notes are not called and the Final Value is less than the Buffer Value. In this case, the Payment at Maturity you will be entitled to receive will be less than the Principal Amount and you will lose 1.3333% for each 1% that the Reference Return is less than -25.00%. You may lose up to 100% of your investment at maturity. Even with the Coupons received prior to or at maturity, your return on the Notes may be negative in this case.

**The Notes may be called prior to the Maturity Date.**

If the Notes are called early, the holding period over which you may receive coupon payments could be as little as approximately 6 months. There is no guarantee that you would be able to reinvest the proceeds from an investment in the Notes at a comparable return for a similar level of risk in the event the Notes are called prior to the Maturity Date.

**Your return on the Notes is limited to the Principal Amount plus the Coupons, regardless of any appreciation in the value of the Reference Asset.**

For each $1,000 Principal Amount, you will receive $1,000 at maturity plus the final Coupon, regardless of any appreciation in the value of the Reference Asset, which may be significant. Accordingly, the return on the Notes may be significantly less than the return on a direct investment in the stocks included in the Reference Asset during the term of the Notes.

**Higher Coupon Rates or lower Buffer Values are generally associated with Reference Assets with greater expected volatility and therefore can indicate a greater risk of loss.**

"Volatility" refers to the frequency and magnitude of changes in the value of the Reference Asset. The greater the expected volatility with respect to the Reference Asset on the Trade Date, the higher the expectation as of the Trade Date that the value of the Reference Asset could close below the Buffer Value on the Final Valuation Date, indicating a higher expected risk of non-payment of Coupons or loss on the Notes. This greater expected risk will generally be reflected in a higher Coupon Rate than the yield payable on our conventional debt securities with a similar maturity, or in more favorable terms (such as a lower Buffer Value or a higher Coupon Rate) than for similar securities linked to the performance of the Reference Asset with a lower expected volatility as of the Trade Date. You should therefore understand that a relatively higher Coupon Rate may indicate an increased risk of loss. Further, a relatively lower Buffer Value may not necessarily indicate that the Notes have a greater likelihood of a repayment of principal at maturity. The volatility of the Reference Asset can change significantly over the term of the Notes. The value of the Reference Asset for your Notes could fall sharply, which could result in a significant loss of principal. You should be willing to accept the downside market risk of the Reference Asset and the potential to lose some or all of your principal at maturity.

**The amount payable on the Notes is not linked to the values of the Reference Asset at any time other than the Final Valuation Date.**

The payments on the Notes will be based on the Official Closing Prices of the Reference Asset on the Final Valuation Date, subject to postponement certain Market Disruption Events. If the Notes are not called, even if the value of the Reference Asset is greater than or equal to the Buffer Value during the term of the Notes other than on the Final Valuation Date but then decreases on the Final Valuation Date to a value that is less than the Buffer Value, the Payment at Maturity will be less, possibly significantly less, than it would have been had the Payment at Maturity been linked to the value of the Reference Asset prior to such decrease.

***Risks Relating to the Reference Asset***

**Changes that affect the Reference Asset may affect the value of the Reference Asset and the market value of the Notes and the amount you will receive on the Notes and the amount you will receive at maturity.**

The policies of the reference sponsor of the Reference Asset, concerning additions, deletions and substitutions of the stocks included in the Reference Asset and the manner in which the reference sponsor takes account of certain changes affecting those stocks may affect the value of the Reference Asset. The policies of the reference sponsor could also affect the value of the Reference Asset . The reference sponsor may discontinue or suspend calculation or dissemination of the Reference Asset. Any such actions could affect the value of the Reference Asset and the value of and the return on the Notes.

**Risks associated with non-U.S. companies.**

The value of the EFA depends upon the stocks of non-U.S. companies, and thus involves risks associated with the home countries of those non-U.S. companies. The prices of these non-U.S. stocks may be affected by political, economic, financial and social factors in the home country of each applicable company, including changes in that country's government, economic and fiscal policies, currency exchange laws or other laws or restrictions, which could affect the value of the Notes. These foreign securities may have less liquidity and could be more volatile than many of the securities traded in U.S. or other securities markets. Direct or indirect government intervention to stabilize the relevant foreign securities markets, as well as cross shareholdings in foreign companies, may affect trading levels or prices and volumes in those markets. The other special risks associated with foreign securities may include, but are not limited to: less liquidity and smaller market capitalizations; less rigorous regulation of securities markets; different accounting and disclosure standards; governmental interference; currency fluctuations; higher inflation; and social, economic and political uncertainties. These factors may adversely affect the performance of the EFA and, as a result, the value of the Notes.

**The Notes will not be adjusted for changes in exchange rates.**

Although the equity securities that are held by the EFA are traded in currencies other than U.S. dollars, and your Notes are denominated in U.S. dollars, the amount payable on your Notes at maturity, if any, will not be adjusted for changes in the exchange rates between the U.S. dollar and the currencies in which these non-U.S. equity securities are denominated. Changes in exchange rates, however, may also reflect changes in the applicable non-U.S. economies that in turn may affect the value of the EFA and therefore the relevant Notes. The amount we pay in respect of your Notes on the maturity date, if any, will be determined solely in accordance with the procedures described in this document.

***General Risk Factors***

**The Notes are subject to the credit risk of HSBC USA Inc.**

The Notes are senior unsecured debt obligations of the Issuer, HSBC, and are not, either directly or indirectly, an obligation of any third party. As further described in the accompanying prospectus supplement and prospectus, the Notes will rank on par with all of the other unsecured and unsubordinated debt obligations of HSBC, except such obligations as may be preferred by operation of law. Any payment to be made on the Notes, including any return of principal at maturity, depends on the ability of HSBC to satisfy its obligations as they come due. As a result, the actual and perceived creditworthiness of HSBC may affect the market value of the Notes and, in the event HSBC were to default on its obligations, you may not receive the amounts owed to you under the terms of the Notes.

**The Notes are not insured or guaranteed by any governmental agency of the United States or any other jurisdiction.**

The Notes are not deposit liabilities or other obligations of a bank and are not insured or guaranteed by the Federal Deposit Insurance Corporation or any other governmental agency or program of the United States or any other jurisdiction. An investment in the Notes is subject to the credit risk of HSBC, and in the event that HSBC is unable to pay its obligations as they become due, you may not receive the full payments due on the Notes.

**The Estimated Initial Value of the Notes, which was determined by us on the Trade Date, is less than the price to public and may differ from the market value of the Notes in the secondary market, if any.**

The Estimated Initial Value of the Notes was calculated by us on the Trade Date and is less than the price to public. The Estimated Initial Value reflects our and our affiliates' internal funding rate, which is the borrowing rate paid to issue market-linked securities, as well as the mid-market value of the embedded derivatives in the Notes. This internal funding rate is typically lower than the rate we would use when we issue conventional fixed or floating rate debt securities. As a result of the difference between our internal funding rate and the rate we would use when we issue conventional fixed or floating rate debt securities, the Estimated Initial Value of the Notes may be lower if it were based on the prices at which our fixed or floating rate debt securities trade in the secondary market. In addition, if we were to use the rate we use for our conventional fixed or floating rate debt issuances, we would expect the economic terms of the Notes to be more favorable to you. We determined the value of the embedded derivatives in the Notes by reference to our or our affiliates' internal pricing models. These pricing models consider certain assumptions and variables, which can include volatility and interest rates. Different pricing models and assumptions could provide valuations for the Notes that are different from our Estimated Initial Value. These pricing models rely in part on certain forecasts about future events, which may prove to be incorrect. The Estimated Initial Value does not represent a minimum price at which we or any of our affiliates would be willing to purchase your Notes in the secondary market (if any exists) at any time.

**The price of your Notes in the secondary market, if any, immediately after the Trade Date is expected to be less than the price to public.**

The price to public takes into account certain costs. These costs, which will be used or retained by us or one of our affiliates, include the underwriting discount, our affiliates' projected hedging profits (which may or may not be realized) for assuming risks inherent in hedging

our obligations under the Notes, and the costs associated with structuring and hedging our obligations under the Notes. If you were to sell your Notes in the secondary market, if any, the price you would receive for your Notes may be less than the price you paid for them because secondary market prices will not take into account these costs. The price of your Notes in the secondary market, if any, at any time after issuance will vary based on many factors, including the value of the Reference Asset and changes in market conditions, and cannot be predicted with accuracy. The Notes are not designed to be short-term trading instruments, and you should, therefore, be able and willing to hold the Notes to maturity. Any sale of the Notes prior to maturity could result in a loss to you.

**If we were to repurchase your Notes immediately after the Original Issue Date, the price you receive may be higher than the Estimated Initial Value of the Notes.**

Assuming that all relevant factors remain constant after the Original Issue Date, the price at which HSBC Securities (USA) Inc. may initially buy or sell the Notes in the secondary market, if any, and the value that may initially be used for customer account statements, if any, may exceed the Estimated Initial Value on the Trade Date for a temporary period expected to be approximately 3 months after the Original Issue Date. This temporary price difference may exist because, in our discretion, we may elect to effectively reimburse to investors a portion of the estimated cost of hedging our obligations under the Notes and other costs in connection with the Notes that we will no longer expect to incur over the term of the Notes. We will make such discretionary election and determine this temporary reimbursement period on the basis of a number of factors, including the tenor of the Notes and any agreement we may have with the distributors of the Notes. The amount of our estimated costs which we effectively reimburse to investors in this way may not be allocated ratably throughout the reimbursement period, and we may discontinue such reimbursement at any time or revise the duration of the reimbursement period after the Original Issue Date of the Notes based on changes in market conditions and other factors that cannot be predicted.

**You will not have any ownership interest in the stocks included in the Reference Asset.**

As a holder of the Notes, you will not have any ownership interest in the stocks included in the Reference Asset, such as rights to vote, dividend payments or other distributions. Because the return on the Notes will not reflect any dividends on those stocks, the Notes may underperform an investment in the stocks included in the Reference Asset.

**The Notes lack liquidity.**

The Notes will not be listed on any securities exchange or automated quotation system. HSBC Securities (USA) Inc. is not required to offer to purchase the Notes in the secondary market, if any exists. Even if there is a secondary market, it may not provide enough liquidity to allow you to trade or sell the Notes easily. Because other dealers are not likely to make a secondary market for the Notes, the price at which you may be able to trade your Notes is likely to depend on the price, if any, at which HSBC Securities (USA) Inc. is willing to buy the Notes.

**Potential conflicts of interest may exist.**

An affiliate of HSBC has a minority equity interest in the owner of an electronic platform, through which we may make available certain structured investments offering materials. HSBC and its affiliates play a variety of roles in connection with the issuance of the Notes, including acting as calculation agent and hedging our obligations under the Notes. In performing these duties, the economic interests of the calculation agent and other affiliates of ours are potentially adverse to your interests as an investor in the Notes. We will not have any obligation to consider your interests as a holder of the Notes in taking any action that might affect the value of your Notes.

**Uncertain tax treatment.**

For a discussion of the U.S. federal income tax consequences of your investment in a Note, please see the discussion under "U.S. Federal Income Tax Considerations" herein and the discussion under "U.S. Federal Income Tax Considerations" in the accompanying prospectus supplement.

**ILLUSTRATIVE EXAMPLES**

The following table and examples are provided for illustrative purposes only and are hypothetical. They do not purport to be representative of every possible scenario concerning increases or decreases in the value of the Reference Asset relative to the Initial Value. We cannot predict the Official Closing Price of the Reference Asset on any Observation Date, including the Final Valuation Date. The assumptions we have made in connection with the illustrations set forth below may not reflect actual events. You should not take this illustration or these examples as an indication or assurance of the expected performance of the Reference Asset or the return on the Notes**.**

The table and examples below illustrate how the Coupon and the Payment at Maturity would be calculated with respect to a $1,000 investment in the Notes, given a range of hypothetical performances of the Reference Asset. The hypothetical returns on the Notes below are numbers, expressed as percentages, that result from comparing the Payment at Maturity per $1,000 Principal Amount to $1,000. You should consider carefully whether the Notes are suitable to your investment goals. The numbers appearing in the following table and examples have been rounded for ease of analysis. The following table and examples assume the following:

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;🞂 | Principal Amount: | &nbsp;&nbsp;$1000 |
| &nbsp;&nbsp;🞂 | Hypothetical Initial Value: | &nbsp;&nbsp;1,000.00\* |
| &nbsp;&nbsp;🞂 | Hypothetical Call Threshold: | &nbsp;&nbsp;1,000.00 (100.00% of the Initial Value) |
| &nbsp;&nbsp;🞂 | Hypothetical Buffer Value: | &nbsp;&nbsp;750.00 (75.00% of the Initial Value) |
| &nbsp;&nbsp;🞂 | Downside Leverage Factor: | &nbsp;&nbsp;1/0.75 (1.3333x) |
| &nbsp;&nbsp;🞂 | Hypothetical Coupon Rate: | &nbsp;&nbsp;7.25% per annum (3.625% for each semi-annual period in which it is payable). If the Notes are not called, the Coupons paid over the term of the Notes would total $108.75 per $1,000 Principal Amount. |

---

\* The hypothetical Initial Value of 1,000.00 used in the examples below has been chosen for illustrative purposes only and does not represent the actual Initial Value of the Reference Asset. The actual Initial Value of the Reference Asset was determined on the Pricing Date and is set forth on PS-3 of this pricing supplement.

**Summary of the Examples**

---

| | | | |
|:---|:---|:---|:---|
|  | &nbsp;&nbsp;**Notes Are Called on an<br> Observation Date** | &nbsp;&nbsp;**Notes Are Not Called on Any <br> Observation Dates** | &nbsp;&nbsp;**Notes Are Not Called on Any <br> Observation Dates** |
|  | &nbsp;&nbsp;**Example 1** | &nbsp;&nbsp;**Example 2** | &nbsp;&nbsp;**Example 3** |
| &nbsp;&nbsp;Initial Value | &nbsp;&nbsp;1000.00 | &nbsp;&nbsp;1000.00 | &nbsp;&nbsp;1000.00 |
| &nbsp;&nbsp;Call Threshold | &nbsp;&nbsp;1000.00 | &nbsp;&nbsp;1000.00 | &nbsp;&nbsp;1000.00 |
| &nbsp;&nbsp;Buffer Value | &nbsp;&nbsp;750.00 | &nbsp;&nbsp;750.00 | &nbsp;&nbsp;750.00 |
| &nbsp;&nbsp;**Official Closing Price / Percentage Change on the:** |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;First Observation Date | &nbsp;&nbsp;787.50 / -21.25% | &nbsp;&nbsp;810.00 / -19.00% | &nbsp;&nbsp;810.00 / -19.00% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Second Observation Date | &nbsp;&nbsp;1,200.00 / 20.00% | &nbsp;&nbsp;787.50 / -21.25% | &nbsp;&nbsp;600.00 / -40.00% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Final Valuation Date | &nbsp;&nbsp;N/A | &nbsp;&nbsp;780.00 / -22.00% | &nbsp;&nbsp;400.00 / -60.00% |
| &nbsp;&nbsp;Coupon Payment Amounts Prior to Maturity or Call | &nbsp;&nbsp;1 x $36.25 = $36.25 | &nbsp;&nbsp;2 x $36.25 = $72.50 | &nbsp;&nbsp;2 x $36.25 = $72.50 |
| &nbsp;&nbsp;Payment if Notes are Called | &nbsp;&nbsp;$1036.25 | &nbsp;&nbsp;N/A | &nbsp;&nbsp;N/A |
| &nbsp;&nbsp;Payment at Maturity | &nbsp;&nbsp;N/A | &nbsp;&nbsp;$1036.25 | &nbsp;&nbsp;$1,000 + [$1,000 x<br> (-60.00% +25.00%) x 1.3333] + $36.25 = $569.58 |
| &nbsp;&nbsp;Return of the Notes | &nbsp;&nbsp;7.25% | &nbsp;&nbsp;10.875% | &nbsp;&nbsp;-35.792% |

---

**Example 1—The Official Closing Price of the Reference Asset on the second Observation Date is greater than or equal to the Call Threshold.**

---

| | |
|:---|:---|
| &nbsp;&nbsp;**<u>Initial Value</u>** | &nbsp;&nbsp;**<u>Official Closing Price</u>** |
| &nbsp;&nbsp;1000.00 | &nbsp;&nbsp;1,250.00 (125.00% of Initial Value) |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;**Payment Upon a Call:** | &nbsp;&nbsp;**$1036.25** |

---

Because the Official Closing Price of the Reference Asset on the second Observation Date is at or above the Call Threshold, the Notes will be called and you will receive $1,036.25 per Note, reflecting the Principal Amount plus the Coupon. When added to the Coupon payments of $36.25 received in respect of the previous Coupon Payment Dates, we will have paid you a total of $1,072.50 per Note, resulting in a 7.25% return on the Notes. No extra payment will be made on account of the Reference Asset closing above the Initial Value.

**Example 2**— **The Notes are not called and the Final Value is greater than or equal to the Buffer Value.**

---

| | |
|:---|:---|
| &nbsp;&nbsp;**<u>Initial Value</u>** | &nbsp;&nbsp;**<u>Final Value</u>** |
| &nbsp;&nbsp;1000.00 | &nbsp;&nbsp;780.00 (78.00% of Initial Value) |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;Reference Return: | &nbsp;&nbsp;-22.00% |
| &nbsp;&nbsp;**Payment at Maturity:** | &nbsp;&nbsp;**$1036.25** |

---

Because the Final Value is greater than or equal to the Buffer Value, you will receive $1,036.25 per Note, reflecting the Principal Amount plus the final Coupon.

When added to the Coupon payments of $72.50 received prior to maturity, we will have paid you a total of $1,108.75 per Note, resulting in a 10.875% return on the Notes.

**Example 3**—**The Notes are not called and the Final Value is less than the Buffer Value.**

---

| | |
|:---|:---|
| &nbsp;&nbsp;**<u>Initial Value</u>** | &nbsp;&nbsp;**<u>Final Value</u>** |
| &nbsp;&nbsp;1000.00 | &nbsp;&nbsp;400.00 (40.00% of Initial Value) |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;Reference Return: | &nbsp;&nbsp;-60.00% |
| &nbsp;&nbsp;**Payment at Maturity:** | &nbsp;&nbsp;**$569.58** |

---

Because the Final Value is less than the Buffer Value, you will receive $569.58 per $1,000 Principal Amount, calculated as follows:

Final Settlement Value = $1,000 + [$1,000 × (Reference Return + 25.00%)<br> × Downside Leverage Factor]+ final Coupon.

$1,000 + [$1,000 x (-60.00% + 25.00%) x 1.3333] + $36.25= $569.58

When added to the Coupon payments of $72.50 received prior to maturity, we will pay you a total of $642.08, resulting in a -35.792% return on the Notes.

If the Notes are not called and the Final Value is less than the Buffer Value, you will be exposed to any decrease in the value of the Reference Asset on a 1.25:1 basis and could lose up to 100% of your principal at maturity.

**DESCRIPTION OF THE REFERENCE ASSET**

---

| | |
|:---|:---|
| **Description of the EFA** | **Historical Performance of the EFA** |
| The EFA seeks investment results that correspond generally to the price and yield performance, before fees and expenses, of publicly traded securities in the European, Australasian, and Far Eastern markets, as measured by the MSCI EAFE<sup>®</sup> Index. The shares of the EFA are listed and trade on the NYSE Arca under the symbol "EFA." | The following graph sets forth the historical performance of the EFA based on the daily historical closing values from January 30, 2013 through January 30, 2023. We obtained the closing values below from the Bloomberg Professional<sup>®</sup> service. We have not undertaken any independent review of, or made any due diligence inquiry with respect to, the information obtained from the Bloomberg Professional<sup>®</sup> service. |
| ***For more information about the Reference Asset, see "The iShares<sup>®</sup> MSCI EAFE ETF" beginning on page S-35 of the accompanying ETF Underlying Supplement.*** | ![](tm234869d18_424b2img04.jpg) |

---

The historical values of the EFA should not be taken as an indication of future performance, and no assurance can be given as to the Official Closing Price of the EFA on any Observation Date, including the Final Valuation Date.

**EVENTS OF DEFAULT AND ACCELERATION**

If the Notes have become immediately due and payable following an Event of Default (as defined in the accompanying prospectus) with respect to the Notes, the calculation agent will determine the accelerated payment due and payable in the same general manner as described in this document except that in such a case, the scheduled trading day immediately preceding the date of acceleration will be used as the Final Valuation Date for purposes of determining the Reference Return of the Reference Asset, and the accelerated Maturity Date will be three business days after the accelerated Final Valuation Date. If a Market Disruption Event exists with respect to the Reference Asset on that scheduled trading day, then the accelerated Final Valuation Date for the Reference Asset will be postponed for up to five scheduled trading days (in the same manner used for postponing the originally scheduled Final Valuation Date). The accelerated Maturity Date will also be postponed by an equal number of business days following the postponed accelerated Final Valuation Date. If the Notes have become immediately due and payable following an Event of Default, you will not be entitled to any additional payments with respect to the Notes. For more information, see "Description of Debt Securities — Senior Debt Securities — Events of Default" in the accompanying prospectus.

**SUPPLEMENTAL PLAN OF DISTRIBUTION (CONFLICTS OF INTEREST)**

We have appointed HSBC Securities (USA) Inc., an affiliate of HSBC, as the agent for the sale of the Notes. Pursuant to the terms of a distribution agreement, HSBC Securities (USA) Inc. will purchase the Notes from HSBC at the price to public less the underwriting discount set forth on the cover page of this pricing supplement, for distribution to other registered broker-dealers or will offer the Notes directly to investors. HSBC Securities (USA) Inc. has offered the Notes at the price to public set forth on the cover page of this document. HSBC USA Inc. or one of our affiliates may pay varying underwriting discounts of up to 0.375% per $1,000 Principal Amount in connection with the distribution of the Notes to other registered broker-dealers.

An affiliate of HSBC has paid or may pay in the future an amount to broker-dealers in connection with the costs of the continuing implementation of systems to support the Notes.

In addition, HSBC Securities (USA) Inc. or another of its affiliates or agents may use this pricing supplement in market-making transactions after the initial sale of the Notes, but is under no obligation to make a market in the Notes and may discontinue any market-making activities at any time without notice.

See "Supplemental Plan of Distribution (Conflicts of Interest)" on page S-83 in the prospectus supplement

Delivery of the Notes will be made against payment for the Notes on the Original Issue Date set forth on the inside cover page of this document, which is more than two business days following the Trade Date. Under Rule 15c6-1 under the Securities Exchange Act of 1934, trades in the secondary market generally are required to settle in two business days, unless the parties to that trade expressly agree otherwise. Accordingly, purchasers who wish to trade the Notes more than two business days prior to the Original Issue Date will be required to specify an alternate settlement cycle at the time of any such trade to prevent a failed settlement, and should consult their own advisors.

**U.S. FEDERAL INCOME TAX CONSIDERATIONS**

There is no direct legal authority as to the proper tax treatment of the Notes, and therefore significant aspects of the tax treatment of the Notes are uncertain as to both the timing and character of any inclusion in income in respect of the Notes. Under one approach, each Note should be treated as a put option written by you (the "Put Option") that permits us to "cash settle" the Put Option, and a deposit with us of cash in an amount equal to the Principal Amount of the Note (the "Deposit") to secure your potential obligation under the Put Option, as described in the accompanying prospectus supplement under the heading "U.S. Federal Income Tax Considerations — Tax Treatment of U.S. Holders — Certain Notes Treated as a Put Option and a Deposit or an Executory Contract — Certain Notes Treated as a Put Option and a Deposit." We intend to treat the Notes consistent with this approach, and we intend to treat the Deposits as non-contingent debt instruments for U.S. federal income tax purposes. Pursuant to the terms of the Notes, you agree to treat each Note as consisting of the Deposit and the Put Option for all U.S. federal income tax purposes. Subject to the limitations described therein, and based on certain factual representations received from us, in the opinion of our special U.S. tax counsel, Mayer Brown LLP, it is reasonable to treat a Note as consisting of the Deposit and the Put Option for all U.S. federal income tax purposes. Because there are no statutory provisions, regulations, published rulings or judicial decisions addressing the characterization for U.S. federal income tax purposes of securities with terms that are substantially the same as those of the Notes, other characterizations and treatments are possible and the timing and character of income in respect of the Notes might differ from the treatment described above. We do not plan to request a ruling from the Internal Revenue Service (the "IRS") regarding the tax treatment of the Notes, and the IRS or a court may not agree with the tax treatment described herein.

We will not attempt to ascertain whether the Reference Asset or any of the entities whose stock is included in the Reference Asset would be treated as a passive foreign investment company ("PFIC") or United States real property holding corporation ("USRPHC"), both as

defined for U.S. federal income tax purposes. If the Reference Asset or one or more of the entities whose stock is included in the Reference Asset were so treated, certain adverse U.S. federal income tax consequences might apply. You should refer to information filed with the SEC and other authorities by the Reference Asset and the entities whose stock is included in the Reference Asset and consult your tax advisor regarding the possible consequences to you if the Reference Asset or one or more of the entities whose stock is included in the Reference Asset is or becomes a PFIC or a USRPHC.

*U.S. Holders*. Please see the discussion under the heading "U.S. Federal Income Tax Considerations — Tax Treatment of U.S. Holders — Certain Notes Treated as a Put Option and a Deposit or an Executory Contract — Certain Notes Treated as a Put Option and a Deposit" in the accompanying prospectus supplement for further discussion of U.S. federal income tax considerations applicable to U.S. holders (as defined in the accompanying prospectus supplement). For purposes of dividing the annual coupon rate of 7.25% on the Notes among interest on the Deposit and Put Premium, 5.40% constitutes interest on the Deposit and 1.85% constitutes Put Premium.

If the Notes are redeemed prior to maturity, you should recognize the total Put Premium received as short-term capital gain at that time.

*Non-U.S. Holders*. Please see the discussion under the heading "U.S. Federal Income Tax Considerations — Tax Treatment of Non-U.S. Holders" in the accompanying prospectus supplement for further discussion of U.S. federal income tax considerations applicable to non-U.S. holders (as defined in the accompanying prospectus supplement). Because the U.S. federal income tax treatment (including the applicability of withholding) of the coupon payments on the Notes is uncertain, the entire amount of the coupon payments will be subject to U.S. federal income tax withholding at a 30% rate (or at a lower rate under an applicable income tax treaty). We will not pay any additional amounts in respect of such withholding.

Under current law, while the matter is not entirely clear, individual non-U.S. holders, and entities whose property is potentially includible in those individuals' gross estates for U.S. federal estate tax purposes (for example, a trust funded by such an individual and with respect to which the individual has retained certain interests or powers), should note that, absent an applicable treaty benefit, the Notes are likely to be treated as U.S. situs property, subject to U.S. federal estate tax. These individuals and entities should consult their own tax advisors regarding the U.S. federal estate tax consequences of investing in the Notes.

A "dividend equivalent" payment is treated as a dividend from sources within the United States and such payments generally would be subject to a 30% U.S. withholding tax if paid to a non-U.S. holder. Under U.S. Treasury Department regulations, payments (including deemed payments) with respect to equity-linked instruments ("ELIs") that are "specified ELIs" may be treated as dividend equivalents if such specified ELIs reference an interest in an "underlying security," which is generally any interest in an entity taxable as a corporation for U.S. federal income tax purposes if a payment with respect to such interest could give rise to a U.S. source dividend. However, Internal Revenue Service guidance provides that withholding on dividend equivalent payments will not apply to specified ELIs that are not delta-one instruments and that are issued before January 1, 2025. Based on the Issuer's determination that the Notes are not "delta-one" instruments, non-U.S. holders should not be subject to withholding on dividend equivalent payments, if any, under the Notes. However, it is possible that the Notes could be treated as deemed reissued for U.S. federal income tax purposes upon the occurrence of certain events affecting the Reference Asset or the Notes, and following such occurrence the Notes could be treated as subject to withholding on dividend equivalent payments. Non-U.S. holders that enter, or have entered, into other transactions in respect of the Reference Asset or the Notes should consult their tax advisors as to the application of the dividend equivalent withholding tax in the context of the Notes and their other transactions. If any payments are treated as dividend equivalents subject to withholding, we (or the applicable paying agent) would be entitled to withhold taxes without being required to pay any additional amounts with respect to amounts so withheld.

For a discussion of the U.S. federal income tax consequences of your investment in a Note, please see the discussion under "U.S Federal Income Tax Considerations" in the accompanying prospectus supplement.

PROSPECTIVE PURCHASERS OF NOTES SHOULD CONSULT THEIR TAX ADVISORS AS TO THE FEDERAL, STATE, LOCAL, AND OTHER TAX CONSEQUENCES TO THEM OF THE PURCHASE, OWNERSHIP AND DISPOSITION OF NOTES.

**VALIDITY OF THE NOTES**

In the opinion of Mayer Brown LLP, as counsel to the Issuer, when this pricing supplement has been attached to, and duly notated on, the master note that represents the Notes pursuant to the Senior Indenture referred to in the prospectus supplement dated February 23, 2021, and issued and paid for as contemplated herein, the Notes offered by this pricing supplement will be valid, binding and enforceable obligations of the Issuer, entitled to the benefits of the Senior Indenture, subject to applicable bankruptcy, insolvency and similar laws affecting creditors' rights generally, concepts of reasonableness and equitable principles of general applicability (including, without limitation, concepts of good faith, fair dealing and the lack of bad faith). This opinion is given as of the date hereof and is limited to the laws of the State of New York, the Maryland General Corporation Law (including the statutory provisions, all applicable provisions of the Maryland Constitution and the reported judicial decisions interpreting the foregoing) and the federal laws of the United States of America. This opinion is subject to customary assumptions about the trustee's authorization, execution and delivery of the Senior Indenture and the genuineness of signatures and to such counsel's reliance on the Issuer and other sources as to certain factual matters,

all as stated in the legal opinion dated February 23, 2021, which has been filed as Exhibit 5.3 to the Issuer's registration statement on Form S-3 dated February 23, 2021.

---

| | | |
|:---|:---|:---|
| **TABLE OF CONTENTS** |  | &nbsp;&nbsp;&nbsp; You should only rely on the information contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. We have not authorized anyone to provide you with information or to make any representation to you that is not contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. If anyone provides you with different or inconsistent information, you should not rely on it. This document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus are not an offer to sell these Notes, and these documents are not soliciting an offer to buy these Notes, in any jurisdiction where the offer or sale is not permitted. You should not, under any circumstances, assume that the information in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus is correct on any date after their respective dates.<br>**HSBC USA Inc.**<br>**$8,325,000 <br> Autocallable Yield Notes Linked to<br> the iShares<sup>®</sup> MSCI EAFE ETF**<br>**January 30, 2023**<br>**Pricing Supplement** |
| **Pricing Supplement** |  | &nbsp;&nbsp;&nbsp; You should only rely on the information contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. We have not authorized anyone to provide you with information or to make any representation to you that is not contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. If anyone provides you with different or inconsistent information, you should not rely on it. This document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus are not an offer to sell these Notes, and these documents are not soliciting an offer to buy these Notes, in any jurisdiction where the offer or sale is not permitted. You should not, under any circumstances, assume that the information in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus is correct on any date after their respective dates.<br>**HSBC USA Inc.**<br>**$8,325,000 <br> Autocallable Yield Notes Linked to<br> the iShares<sup>®</sup> MSCI EAFE ETF**<br>**January 30, 2023**<br>**Pricing Supplement** |
| General | PS-4 | &nbsp;&nbsp;&nbsp; You should only rely on the information contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. We have not authorized anyone to provide you with information or to make any representation to you that is not contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. If anyone provides you with different or inconsistent information, you should not rely on it. This document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus are not an offer to sell these Notes, and these documents are not soliciting an offer to buy these Notes, in any jurisdiction where the offer or sale is not permitted. You should not, under any circumstances, assume that the information in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus is correct on any date after their respective dates.<br>**HSBC USA Inc.**<br>**$8,325,000 <br> Autocallable Yield Notes Linked to<br> the iShares<sup>®</sup> MSCI EAFE ETF**<br>**January 30, 2023**<br>**Pricing Supplement** |
| Payment on the Notes | PS-5 | &nbsp;&nbsp;&nbsp; You should only rely on the information contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. We have not authorized anyone to provide you with information or to make any representation to you that is not contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. If anyone provides you with different or inconsistent information, you should not rely on it. This document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus are not an offer to sell these Notes, and these documents are not soliciting an offer to buy these Notes, in any jurisdiction where the offer or sale is not permitted. You should not, under any circumstances, assume that the information in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus is correct on any date after their respective dates.<br>**HSBC USA Inc.**<br>**$8,325,000 <br> Autocallable Yield Notes Linked to<br> the iShares<sup>®</sup> MSCI EAFE ETF**<br>**January 30, 2023**<br>**Pricing Supplement** |
| Investor Suitability | PS-6 | &nbsp;&nbsp;&nbsp; You should only rely on the information contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. We have not authorized anyone to provide you with information or to make any representation to you that is not contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. If anyone provides you with different or inconsistent information, you should not rely on it. This document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus are not an offer to sell these Notes, and these documents are not soliciting an offer to buy these Notes, in any jurisdiction where the offer or sale is not permitted. You should not, under any circumstances, assume that the information in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus is correct on any date after their respective dates.<br>**HSBC USA Inc.**<br>**$8,325,000 <br> Autocallable Yield Notes Linked to<br> the iShares<sup>®</sup> MSCI EAFE ETF**<br>**January 30, 2023**<br>**Pricing Supplement** |
| Risk Factors | PS-7 | &nbsp;&nbsp;&nbsp; You should only rely on the information contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. We have not authorized anyone to provide you with information or to make any representation to you that is not contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. If anyone provides you with different or inconsistent information, you should not rely on it. This document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus are not an offer to sell these Notes, and these documents are not soliciting an offer to buy these Notes, in any jurisdiction where the offer or sale is not permitted. You should not, under any circumstances, assume that the information in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus is correct on any date after their respective dates.<br>**HSBC USA Inc.**<br>**$8,325,000 <br> Autocallable Yield Notes Linked to<br> the iShares<sup>®</sup> MSCI EAFE ETF**<br>**January 30, 2023**<br>**Pricing Supplement** |
| Illustrative Examples | PS-10 | &nbsp;&nbsp;&nbsp; You should only rely on the information contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. We have not authorized anyone to provide you with information or to make any representation to you that is not contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. If anyone provides you with different or inconsistent information, you should not rely on it. This document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus are not an offer to sell these Notes, and these documents are not soliciting an offer to buy these Notes, in any jurisdiction where the offer or sale is not permitted. You should not, under any circumstances, assume that the information in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus is correct on any date after their respective dates.<br>**HSBC USA Inc.**<br>**$8,325,000 <br> Autocallable Yield Notes Linked to<br> the iShares<sup>®</sup> MSCI EAFE ETF**<br>**January 30, 2023**<br>**Pricing Supplement** |
| Description of the Reference Asset | PS-13 | &nbsp;&nbsp;&nbsp; You should only rely on the information contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. We have not authorized anyone to provide you with information or to make any representation to you that is not contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. If anyone provides you with different or inconsistent information, you should not rely on it. This document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus are not an offer to sell these Notes, and these documents are not soliciting an offer to buy these Notes, in any jurisdiction where the offer or sale is not permitted. You should not, under any circumstances, assume that the information in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus is correct on any date after their respective dates.<br>**HSBC USA Inc.**<br>**$8,325,000 <br> Autocallable Yield Notes Linked to<br> the iShares<sup>®</sup> MSCI EAFE ETF**<br>**January 30, 2023**<br>**Pricing Supplement** |
| Events of Default and Acceleration | PS-14 | &nbsp;&nbsp;&nbsp; You should only rely on the information contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. We have not authorized anyone to provide you with information or to make any representation to you that is not contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. If anyone provides you with different or inconsistent information, you should not rely on it. This document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus are not an offer to sell these Notes, and these documents are not soliciting an offer to buy these Notes, in any jurisdiction where the offer or sale is not permitted. You should not, under any circumstances, assume that the information in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus is correct on any date after their respective dates.<br>**HSBC USA Inc.**<br>**$8,325,000 <br> Autocallable Yield Notes Linked to<br> the iShares<sup>®</sup> MSCI EAFE ETF**<br>**January 30, 2023**<br>**Pricing Supplement** |
| Supplemental Plan of Distribution (Conflicts of Interest) | PS-14 | &nbsp;&nbsp;&nbsp; You should only rely on the information contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. We have not authorized anyone to provide you with information or to make any representation to you that is not contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. If anyone provides you with different or inconsistent information, you should not rely on it. This document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus are not an offer to sell these Notes, and these documents are not soliciting an offer to buy these Notes, in any jurisdiction where the offer or sale is not permitted. You should not, under any circumstances, assume that the information in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus is correct on any date after their respective dates.<br>**HSBC USA Inc.**<br>**$8,325,000 <br> Autocallable Yield Notes Linked to<br> the iShares<sup>®</sup> MSCI EAFE ETF**<br>**January 30, 2023**<br>**Pricing Supplement** |
| U.S. Federal Income Tax Considerations | PS-14 | &nbsp;&nbsp;&nbsp; You should only rely on the information contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. We have not authorized anyone to provide you with information or to make any representation to you that is not contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. If anyone provides you with different or inconsistent information, you should not rely on it. This document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus are not an offer to sell these Notes, and these documents are not soliciting an offer to buy these Notes, in any jurisdiction where the offer or sale is not permitted. You should not, under any circumstances, assume that the information in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus is correct on any date after their respective dates.<br>**HSBC USA Inc.**<br>**$8,325,000 <br> Autocallable Yield Notes Linked to<br> the iShares<sup>®</sup> MSCI EAFE ETF**<br>**January 30, 2023**<br>**Pricing Supplement** |
| Validity of the Notes | PS-15 | &nbsp;&nbsp;&nbsp; You should only rely on the information contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. We have not authorized anyone to provide you with information or to make any representation to you that is not contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. If anyone provides you with different or inconsistent information, you should not rely on it. This document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus are not an offer to sell these Notes, and these documents are not soliciting an offer to buy these Notes, in any jurisdiction where the offer or sale is not permitted. You should not, under any circumstances, assume that the information in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus is correct on any date after their respective dates.<br>**HSBC USA Inc.**<br>**$8,325,000 <br> Autocallable Yield Notes Linked to<br> the iShares<sup>®</sup> MSCI EAFE ETF**<br>**January 30, 2023**<br>**Pricing Supplement** |
| **ETF Underlying Supplement** |  | &nbsp;&nbsp;&nbsp; You should only rely on the information contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. We have not authorized anyone to provide you with information or to make any representation to you that is not contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. If anyone provides you with different or inconsistent information, you should not rely on it. This document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus are not an offer to sell these Notes, and these documents are not soliciting an offer to buy these Notes, in any jurisdiction where the offer or sale is not permitted. You should not, under any circumstances, assume that the information in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus is correct on any date after their respective dates.<br>**HSBC USA Inc.**<br>**$8,325,000 <br> Autocallable Yield Notes Linked to<br> the iShares<sup>®</sup> MSCI EAFE ETF**<br>**January 30, 2023**<br>**Pricing Supplement** |
|  |  | &nbsp;&nbsp;&nbsp; You should only rely on the information contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. We have not authorized anyone to provide you with information or to make any representation to you that is not contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. If anyone provides you with different or inconsistent information, you should not rely on it. This document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus are not an offer to sell these Notes, and these documents are not soliciting an offer to buy these Notes, in any jurisdiction where the offer or sale is not permitted. You should not, under any circumstances, assume that the information in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus is correct on any date after their respective dates.<br>**HSBC USA Inc.**<br>**$8,325,000 <br> Autocallable Yield Notes Linked to<br> the iShares<sup>®</sup> MSCI EAFE ETF**<br>**January 30, 2023**<br>**Pricing Supplement** |
| Risk Factors | S-1 | &nbsp;&nbsp;&nbsp; You should only rely on the information contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. We have not authorized anyone to provide you with information or to make any representation to you that is not contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. If anyone provides you with different or inconsistent information, you should not rely on it. This document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus are not an offer to sell these Notes, and these documents are not soliciting an offer to buy these Notes, in any jurisdiction where the offer or sale is not permitted. You should not, under any circumstances, assume that the information in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus is correct on any date after their respective dates.<br>**HSBC USA Inc.**<br>**$8,325,000 <br> Autocallable Yield Notes Linked to<br> the iShares<sup>®</sup> MSCI EAFE ETF**<br>**January 30, 2023**<br>**Pricing Supplement** |
| Reference Sponsors and Index Funds | S-12 | &nbsp;&nbsp;&nbsp; You should only rely on the information contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. We have not authorized anyone to provide you with information or to make any representation to you that is not contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. If anyone provides you with different or inconsistent information, you should not rely on it. This document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus are not an offer to sell these Notes, and these documents are not soliciting an offer to buy these Notes, in any jurisdiction where the offer or sale is not permitted. You should not, under any circumstances, assume that the information in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus is correct on any date after their respective dates.<br>**HSBC USA Inc.**<br>**$8,325,000 <br> Autocallable Yield Notes Linked to<br> the iShares<sup>®</sup> MSCI EAFE ETF**<br>**January 30, 2023**<br>**Pricing Supplement** |
| The Consumer Staples Select Sector SPDR<sup>®</sup> Fund | S-13 | &nbsp;&nbsp;&nbsp; You should only rely on the information contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. We have not authorized anyone to provide you with information or to make any representation to you that is not contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. If anyone provides you with different or inconsistent information, you should not rely on it. This document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus are not an offer to sell these Notes, and these documents are not soliciting an offer to buy these Notes, in any jurisdiction where the offer or sale is not permitted. You should not, under any circumstances, assume that the information in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus is correct on any date after their respective dates.<br>**HSBC USA Inc.**<br>**$8,325,000 <br> Autocallable Yield Notes Linked to<br> the iShares<sup>®</sup> MSCI EAFE ETF**<br>**January 30, 2023**<br>**Pricing Supplement** |
| The Energy Select Sector SPDR<sup>®</sup> Fund | S-15 | &nbsp;&nbsp;&nbsp; You should only rely on the information contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. We have not authorized anyone to provide you with information or to make any representation to you that is not contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. If anyone provides you with different or inconsistent information, you should not rely on it. This document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus are not an offer to sell these Notes, and these documents are not soliciting an offer to buy these Notes, in any jurisdiction where the offer or sale is not permitted. You should not, under any circumstances, assume that the information in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus is correct on any date after their respective dates.<br>**HSBC USA Inc.**<br>**$8,325,000 <br> Autocallable Yield Notes Linked to<br> the iShares<sup>®</sup> MSCI EAFE ETF**<br>**January 30, 2023**<br>**Pricing Supplement** |
| The Financial Select Sector SPDR<sup>®</sup> Fund | S-17 | &nbsp;&nbsp;&nbsp; You should only rely on the information contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. We have not authorized anyone to provide you with information or to make any representation to you that is not contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. If anyone provides you with different or inconsistent information, you should not rely on it. This document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus are not an offer to sell these Notes, and these documents are not soliciting an offer to buy these Notes, in any jurisdiction where the offer or sale is not permitted. You should not, under any circumstances, assume that the information in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus is correct on any date after their respective dates.<br>**HSBC USA Inc.**<br>**$8,325,000 <br> Autocallable Yield Notes Linked to<br> the iShares<sup>®</sup> MSCI EAFE ETF**<br>**January 30, 2023**<br>**Pricing Supplement** |
| The Health Care Select Sector SPDR<sup>®</sup> Fund | S-19 | &nbsp;&nbsp;&nbsp; You should only rely on the information contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. We have not authorized anyone to provide you with information or to make any representation to you that is not contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. If anyone provides you with different or inconsistent information, you should not rely on it. This document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus are not an offer to sell these Notes, and these documents are not soliciting an offer to buy these Notes, in any jurisdiction where the offer or sale is not permitted. You should not, under any circumstances, assume that the information in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus is correct on any date after their respective dates.<br>**HSBC USA Inc.**<br>**$8,325,000 <br> Autocallable Yield Notes Linked to<br> the iShares<sup>®</sup> MSCI EAFE ETF**<br>**January 30, 2023**<br>**Pricing Supplement** |
| The Technology Select Sector SPDR<sup>®</sup> Fund | S-21 | &nbsp;&nbsp;&nbsp; You should only rely on the information contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. We have not authorized anyone to provide you with information or to make any representation to you that is not contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. If anyone provides you with different or inconsistent information, you should not rely on it. This document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus are not an offer to sell these Notes, and these documents are not soliciting an offer to buy these Notes, in any jurisdiction where the offer or sale is not permitted. You should not, under any circumstances, assume that the information in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus is correct on any date after their respective dates.<br>**HSBC USA Inc.**<br>**$8,325,000 <br> Autocallable Yield Notes Linked to<br> the iShares<sup>®</sup> MSCI EAFE ETF**<br>**January 30, 2023**<br>**Pricing Supplement** |
| The Utilities Select Sector SPDR<sup>®</sup> Fund | S-23 | &nbsp;&nbsp;&nbsp; You should only rely on the information contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. We have not authorized anyone to provide you with information or to make any representation to you that is not contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. If anyone provides you with different or inconsistent information, you should not rely on it. This document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus are not an offer to sell these Notes, and these documents are not soliciting an offer to buy these Notes, in any jurisdiction where the offer or sale is not permitted. You should not, under any circumstances, assume that the information in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus is correct on any date after their respective dates.<br>**HSBC USA Inc.**<br>**$8,325,000 <br> Autocallable Yield Notes Linked to<br> the iShares<sup>®</sup> MSCI EAFE ETF**<br>**January 30, 2023**<br>**Pricing Supplement** |
| The iShares<sup>®</sup> China Large-Cap ETF | S-25 | &nbsp;&nbsp;&nbsp; You should only rely on the information contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. We have not authorized anyone to provide you with information or to make any representation to you that is not contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. If anyone provides you with different or inconsistent information, you should not rely on it. This document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus are not an offer to sell these Notes, and these documents are not soliciting an offer to buy these Notes, in any jurisdiction where the offer or sale is not permitted. You should not, under any circumstances, assume that the information in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus is correct on any date after their respective dates.<br>**HSBC USA Inc.**<br>**$8,325,000 <br> Autocallable Yield Notes Linked to<br> the iShares<sup>®</sup> MSCI EAFE ETF**<br>**January 30, 2023**<br>**Pricing Supplement** |
| The iShares<sup>®</sup> Global Clean Energy ETF | S-28 | &nbsp;&nbsp;&nbsp; You should only rely on the information contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. We have not authorized anyone to provide you with information or to make any representation to you that is not contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. If anyone provides you with different or inconsistent information, you should not rely on it. This document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus are not an offer to sell these Notes, and these documents are not soliciting an offer to buy these Notes, in any jurisdiction where the offer or sale is not permitted. You should not, under any circumstances, assume that the information in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus is correct on any date after their respective dates.<br>**HSBC USA Inc.**<br>**$8,325,000 <br> Autocallable Yield Notes Linked to<br> the iShares<sup>®</sup> MSCI EAFE ETF**<br>**January 30, 2023**<br>**Pricing Supplement** |
| The iShares<sup>®</sup> Latin America 40 ETF | S-31 | &nbsp;&nbsp;&nbsp; You should only rely on the information contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. We have not authorized anyone to provide you with information or to make any representation to you that is not contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. If anyone provides you with different or inconsistent information, you should not rely on it. This document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus are not an offer to sell these Notes, and these documents are not soliciting an offer to buy these Notes, in any jurisdiction where the offer or sale is not permitted. You should not, under any circumstances, assume that the information in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus is correct on any date after their respective dates.<br>**HSBC USA Inc.**<br>**$8,325,000 <br> Autocallable Yield Notes Linked to<br> the iShares<sup>®</sup> MSCI EAFE ETF**<br>**January 30, 2023**<br>**Pricing Supplement** |
| The iShares<sup>®</sup> MSCI Brazil ETF | S-33 | &nbsp;&nbsp;&nbsp; You should only rely on the information contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. We have not authorized anyone to provide you with information or to make any representation to you that is not contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. If anyone provides you with different or inconsistent information, you should not rely on it. This document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus are not an offer to sell these Notes, and these documents are not soliciting an offer to buy these Notes, in any jurisdiction where the offer or sale is not permitted. You should not, under any circumstances, assume that the information in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus is correct on any date after their respective dates.<br>**HSBC USA Inc.**<br>**$8,325,000 <br> Autocallable Yield Notes Linked to<br> the iShares<sup>®</sup> MSCI EAFE ETF**<br>**January 30, 2023**<br>**Pricing Supplement** |
| The iShares<sup>®</sup> MSCI EAFE ETF | S-35 | &nbsp;&nbsp;&nbsp; You should only rely on the information contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. We have not authorized anyone to provide you with information or to make any representation to you that is not contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. If anyone provides you with different or inconsistent information, you should not rely on it. This document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus are not an offer to sell these Notes, and these documents are not soliciting an offer to buy these Notes, in any jurisdiction where the offer or sale is not permitted. You should not, under any circumstances, assume that the information in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus is correct on any date after their respective dates.<br>**HSBC USA Inc.**<br>**$8,325,000 <br> Autocallable Yield Notes Linked to<br> the iShares<sup>®</sup> MSCI EAFE ETF**<br>**January 30, 2023**<br>**Pricing Supplement** |
| The iShares<sup>®</sup> MSCI Emerging Markets ETF | S-40 | &nbsp;&nbsp;&nbsp; You should only rely on the information contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. We have not authorized anyone to provide you with information or to make any representation to you that is not contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. If anyone provides you with different or inconsistent information, you should not rely on it. This document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus are not an offer to sell these Notes, and these documents are not soliciting an offer to buy these Notes, in any jurisdiction where the offer or sale is not permitted. You should not, under any circumstances, assume that the information in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus is correct on any date after their respective dates.<br>**HSBC USA Inc.**<br>**$8,325,000 <br> Autocallable Yield Notes Linked to<br> the iShares<sup>®</sup> MSCI EAFE ETF**<br>**January 30, 2023**<br>**Pricing Supplement** |
| The iShares<sup>®</sup> MSCI Mexico ETF | S-41 | &nbsp;&nbsp;&nbsp; You should only rely on the information contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. We have not authorized anyone to provide you with information or to make any representation to you that is not contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. If anyone provides you with different or inconsistent information, you should not rely on it. This document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus are not an offer to sell these Notes, and these documents are not soliciting an offer to buy these Notes, in any jurisdiction where the offer or sale is not permitted. You should not, under any circumstances, assume that the information in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus is correct on any date after their respective dates.<br>**HSBC USA Inc.**<br>**$8,325,000 <br> Autocallable Yield Notes Linked to<br> the iShares<sup>®</sup> MSCI EAFE ETF**<br>**January 30, 2023**<br>**Pricing Supplement** |
| The iShares<sup>®</sup> Russell 2000 ETF | S-44 | &nbsp;&nbsp;&nbsp; You should only rely on the information contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. We have not authorized anyone to provide you with information or to make any representation to you that is not contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. If anyone provides you with different or inconsistent information, you should not rely on it. This document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus are not an offer to sell these Notes, and these documents are not soliciting an offer to buy these Notes, in any jurisdiction where the offer or sale is not permitted. You should not, under any circumstances, assume that the information in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus is correct on any date after their respective dates.<br>**HSBC USA Inc.**<br>**$8,325,000 <br> Autocallable Yield Notes Linked to<br> the iShares<sup>®</sup> MSCI EAFE ETF**<br>**January 30, 2023**<br>**Pricing Supplement** |
| The iShares<sup>®</sup> Transportation Average ETF | S-47 | &nbsp;&nbsp;&nbsp; You should only rely on the information contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. We have not authorized anyone to provide you with information or to make any representation to you that is not contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. If anyone provides you with different or inconsistent information, you should not rely on it. This document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus are not an offer to sell these Notes, and these documents are not soliciting an offer to buy these Notes, in any jurisdiction where the offer or sale is not permitted. You should not, under any circumstances, assume that the information in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus is correct on any date after their respective dates.<br>**HSBC USA Inc.**<br>**$8,325,000 <br> Autocallable Yield Notes Linked to<br> the iShares<sup>®</sup> MSCI EAFE ETF**<br>**January 30, 2023**<br>**Pricing Supplement** |
| The iShares<sup>®</sup> U.S. Real Estate ETF | S-49 | &nbsp;&nbsp;&nbsp; You should only rely on the information contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. We have not authorized anyone to provide you with information or to make any representation to you that is not contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. If anyone provides you with different or inconsistent information, you should not rely on it. This document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus are not an offer to sell these Notes, and these documents are not soliciting an offer to buy these Notes, in any jurisdiction where the offer or sale is not permitted. You should not, under any circumstances, assume that the information in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus is correct on any date after their respective dates.<br>**HSBC USA Inc.**<br>**$8,325,000 <br> Autocallable Yield Notes Linked to<br> the iShares<sup>®</sup> MSCI EAFE ETF**<br>**January 30, 2023**<br>**Pricing Supplement** |
| The Invesco QQQ Trust℠, Series I | S-51 | &nbsp;&nbsp;&nbsp; You should only rely on the information contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. We have not authorized anyone to provide you with information or to make any representation to you that is not contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. If anyone provides you with different or inconsistent information, you should not rely on it. This document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus are not an offer to sell these Notes, and these documents are not soliciting an offer to buy these Notes, in any jurisdiction where the offer or sale is not permitted. You should not, under any circumstances, assume that the information in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus is correct on any date after their respective dates.<br>**HSBC USA Inc.**<br>**$8,325,000 <br> Autocallable Yield Notes Linked to<br> the iShares<sup>®</sup> MSCI EAFE ETF**<br>**January 30, 2023**<br>**Pricing Supplement** |
| The SPDR<sup>®</sup> Dow Jones<sup>®</sup> Industrial Average ETF Trust | S-54 | &nbsp;&nbsp;&nbsp; You should only rely on the information contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. We have not authorized anyone to provide you with information or to make any representation to you that is not contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. If anyone provides you with different or inconsistent information, you should not rely on it. This document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus are not an offer to sell these Notes, and these documents are not soliciting an offer to buy these Notes, in any jurisdiction where the offer or sale is not permitted. You should not, under any circumstances, assume that the information in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus is correct on any date after their respective dates.<br>**HSBC USA Inc.**<br>**$8,325,000 <br> Autocallable Yield Notes Linked to<br> the iShares<sup>®</sup> MSCI EAFE ETF**<br>**January 30, 2023**<br>**Pricing Supplement** |
| The SPDR<sup>®</sup> S&P 500<sup>®</sup> ETF Trust | S-56 | &nbsp;&nbsp;&nbsp; You should only rely on the information contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. We have not authorized anyone to provide you with information or to make any representation to you that is not contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. If anyone provides you with different or inconsistent information, you should not rely on it. This document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus are not an offer to sell these Notes, and these documents are not soliciting an offer to buy these Notes, in any jurisdiction where the offer or sale is not permitted. You should not, under any circumstances, assume that the information in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus is correct on any date after their respective dates.<br>**HSBC USA Inc.**<br>**$8,325,000 <br> Autocallable Yield Notes Linked to<br> the iShares<sup>®</sup> MSCI EAFE ETF**<br>**January 30, 2023**<br>**Pricing Supplement** |
| The SPDR<sup>®</sup> S&P<sup>®</sup> Bank ETF | S-62 | &nbsp;&nbsp;&nbsp; You should only rely on the information contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. We have not authorized anyone to provide you with information or to make any representation to you that is not contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. If anyone provides you with different or inconsistent information, you should not rely on it. This document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus are not an offer to sell these Notes, and these documents are not soliciting an offer to buy these Notes, in any jurisdiction where the offer or sale is not permitted. You should not, under any circumstances, assume that the information in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus is correct on any date after their respective dates.<br>**HSBC USA Inc.**<br>**$8,325,000 <br> Autocallable Yield Notes Linked to<br> the iShares<sup>®</sup> MSCI EAFE ETF**<br>**January 30, 2023**<br>**Pricing Supplement** |
| The SPDR<sup>®</sup> S&P<sup>®</sup> Regional Banking ETF | S-65 | &nbsp;&nbsp;&nbsp; You should only rely on the information contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. We have not authorized anyone to provide you with information or to make any representation to you that is not contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. If anyone provides you with different or inconsistent information, you should not rely on it. This document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus are not an offer to sell these Notes, and these documents are not soliciting an offer to buy these Notes, in any jurisdiction where the offer or sale is not permitted. You should not, under any circumstances, assume that the information in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus is correct on any date after their respective dates.<br>**HSBC USA Inc.**<br>**$8,325,000 <br> Autocallable Yield Notes Linked to<br> the iShares<sup>®</sup> MSCI EAFE ETF**<br>**January 30, 2023**<br>**Pricing Supplement** |
| The SPDR<sup>®</sup> S&P Midcap 400<sup>®</sup> ETF Trust | S-66 | &nbsp;&nbsp;&nbsp; You should only rely on the information contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. We have not authorized anyone to provide you with information or to make any representation to you that is not contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. If anyone provides you with different or inconsistent information, you should not rely on it. This document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus are not an offer to sell these Notes, and these documents are not soliciting an offer to buy these Notes, in any jurisdiction where the offer or sale is not permitted. You should not, under any circumstances, assume that the information in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus is correct on any date after their respective dates.<br>**HSBC USA Inc.**<br>**$8,325,000 <br> Autocallable Yield Notes Linked to<br> the iShares<sup>®</sup> MSCI EAFE ETF**<br>**January 30, 2023**<br>**Pricing Supplement** |
| The SPDR<sup>®</sup> S&P<sup>®</sup> Biotech ETF | S-73 | &nbsp;&nbsp;&nbsp; You should only rely on the information contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. We have not authorized anyone to provide you with information or to make any representation to you that is not contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. If anyone provides you with different or inconsistent information, you should not rely on it. This document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus are not an offer to sell these Notes, and these documents are not soliciting an offer to buy these Notes, in any jurisdiction where the offer or sale is not permitted. You should not, under any circumstances, assume that the information in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus is correct on any date after their respective dates.<br>**HSBC USA Inc.**<br>**$8,325,000 <br> Autocallable Yield Notes Linked to<br> the iShares<sup>®</sup> MSCI EAFE ETF**<br>**January 30, 2023**<br>**Pricing Supplement** |
| The SPDR<sup>®</sup> S&P<sup>®</sup> Oil & Gas Exploration & Production ETF | S-74 | &nbsp;&nbsp;&nbsp; You should only rely on the information contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. We have not authorized anyone to provide you with information or to make any representation to you that is not contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. If anyone provides you with different or inconsistent information, you should not rely on it. This document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus are not an offer to sell these Notes, and these documents are not soliciting an offer to buy these Notes, in any jurisdiction where the offer or sale is not permitted. You should not, under any circumstances, assume that the information in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus is correct on any date after their respective dates.<br>**HSBC USA Inc.**<br>**$8,325,000 <br> Autocallable Yield Notes Linked to<br> the iShares<sup>®</sup> MSCI EAFE ETF**<br>**January 30, 2023**<br>**Pricing Supplement** |
| The VanEck<sup>®</sup> Vectors Gold Miners ETF | S-75 | &nbsp;&nbsp;&nbsp; You should only rely on the information contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. We have not authorized anyone to provide you with information or to make any representation to you that is not contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. If anyone provides you with different or inconsistent information, you should not rely on it. This document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus are not an offer to sell these Notes, and these documents are not soliciting an offer to buy these Notes, in any jurisdiction where the offer or sale is not permitted. You should not, under any circumstances, assume that the information in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus is correct on any date after their respective dates.<br>**HSBC USA Inc.**<br>**$8,325,000 <br> Autocallable Yield Notes Linked to<br> the iShares<sup>®</sup> MSCI EAFE ETF**<br>**January 30, 2023**<br>**Pricing Supplement** |
| The Vanguard<sup>®</sup> FTSE Emerging Markets ETF | S-78 | &nbsp;&nbsp;&nbsp; You should only rely on the information contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. We have not authorized anyone to provide you with information or to make any representation to you that is not contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. If anyone provides you with different or inconsistent information, you should not rely on it. This document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus are not an offer to sell these Notes, and these documents are not soliciting an offer to buy these Notes, in any jurisdiction where the offer or sale is not permitted. You should not, under any circumstances, assume that the information in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus is correct on any date after their respective dates.<br>**HSBC USA Inc.**<br>**$8,325,000 <br> Autocallable Yield Notes Linked to<br> the iShares<sup>®</sup> MSCI EAFE ETF**<br>**January 30, 2023**<br>**Pricing Supplement** |
| The WisdomTree<sup>®</sup> Japan Hedged Equity Fund | S-80 | &nbsp;&nbsp;&nbsp; You should only rely on the information contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. We have not authorized anyone to provide you with information or to make any representation to you that is not contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. If anyone provides you with different or inconsistent information, you should not rely on it. This document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus are not an offer to sell these Notes, and these documents are not soliciting an offer to buy these Notes, in any jurisdiction where the offer or sale is not permitted. You should not, under any circumstances, assume that the information in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus is correct on any date after their respective dates.<br>**HSBC USA Inc.**<br>**$8,325,000 <br> Autocallable Yield Notes Linked to<br> the iShares<sup>®</sup> MSCI EAFE ETF**<br>**January 30, 2023**<br>**Pricing Supplement** |
| Additional Terms of the Notes | S-84 | &nbsp;&nbsp;&nbsp; You should only rely on the information contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. We have not authorized anyone to provide you with information or to make any representation to you that is not contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. If anyone provides you with different or inconsistent information, you should not rely on it. This document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus are not an offer to sell these Notes, and these documents are not soliciting an offer to buy these Notes, in any jurisdiction where the offer or sale is not permitted. You should not, under any circumstances, assume that the information in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus is correct on any date after their respective dates.<br>**HSBC USA Inc.**<br>**$8,325,000 <br> Autocallable Yield Notes Linked to<br> the iShares<sup>®</sup> MSCI EAFE ETF**<br>**January 30, 2023**<br>**Pricing Supplement** |
| **Prospectus Supplement** |  | &nbsp;&nbsp;&nbsp; You should only rely on the information contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. We have not authorized anyone to provide you with information or to make any representation to you that is not contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. If anyone provides you with different or inconsistent information, you should not rely on it. This document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus are not an offer to sell these Notes, and these documents are not soliciting an offer to buy these Notes, in any jurisdiction where the offer or sale is not permitted. You should not, under any circumstances, assume that the information in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus is correct on any date after their respective dates.<br>**HSBC USA Inc.**<br>**$8,325,000 <br> Autocallable Yield Notes Linked to<br> the iShares<sup>®</sup> MSCI EAFE ETF**<br>**January 30, 2023**<br>**Pricing Supplement** |
|  |  | &nbsp;&nbsp;&nbsp; You should only rely on the information contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. We have not authorized anyone to provide you with information or to make any representation to you that is not contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. If anyone provides you with different or inconsistent information, you should not rely on it. This document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus are not an offer to sell these Notes, and these documents are not soliciting an offer to buy these Notes, in any jurisdiction where the offer or sale is not permitted. You should not, under any circumstances, assume that the information in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus is correct on any date after their respective dates.<br>**HSBC USA Inc.**<br>**$8,325,000 <br> Autocallable Yield Notes Linked to<br> the iShares<sup>®</sup> MSCI EAFE ETF**<br>**January 30, 2023**<br>**Pricing Supplement** |
| Risk Factors | S-1 | &nbsp;&nbsp;&nbsp; You should only rely on the information contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. We have not authorized anyone to provide you with information or to make any representation to you that is not contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. If anyone provides you with different or inconsistent information, you should not rely on it. This document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus are not an offer to sell these Notes, and these documents are not soliciting an offer to buy these Notes, in any jurisdiction where the offer or sale is not permitted. You should not, under any circumstances, assume that the information in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus is correct on any date after their respective dates.<br>**HSBC USA Inc.**<br>**$8,325,000 <br> Autocallable Yield Notes Linked to<br> the iShares<sup>®</sup> MSCI EAFE ETF**<br>**January 30, 2023**<br>**Pricing Supplement** |
| Pricing Supplement | S-12 | &nbsp;&nbsp;&nbsp; You should only rely on the information contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. We have not authorized anyone to provide you with information or to make any representation to you that is not contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. If anyone provides you with different or inconsistent information, you should not rely on it. This document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus are not an offer to sell these Notes, and these documents are not soliciting an offer to buy these Notes, in any jurisdiction where the offer or sale is not permitted. You should not, under any circumstances, assume that the information in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus is correct on any date after their respective dates.<br>**HSBC USA Inc.**<br>**$8,325,000 <br> Autocallable Yield Notes Linked to<br> the iShares<sup>®</sup> MSCI EAFE ETF**<br>**January 30, 2023**<br>**Pricing Supplement** |
| Description of Notes | S-14 | &nbsp;&nbsp;&nbsp; You should only rely on the information contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. We have not authorized anyone to provide you with information or to make any representation to you that is not contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. If anyone provides you with different or inconsistent information, you should not rely on it. This document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus are not an offer to sell these Notes, and these documents are not soliciting an offer to buy these Notes, in any jurisdiction where the offer or sale is not permitted. You should not, under any circumstances, assume that the information in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus is correct on any date after their respective dates.<br>**HSBC USA Inc.**<br>**$8,325,000 <br> Autocallable Yield Notes Linked to<br> the iShares<sup>®</sup> MSCI EAFE ETF**<br>**January 30, 2023**<br>**Pricing Supplement** |
| Use of Proceeds and Hedging | S-55 | &nbsp;&nbsp;&nbsp; You should only rely on the information contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. We have not authorized anyone to provide you with information or to make any representation to you that is not contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. If anyone provides you with different or inconsistent information, you should not rely on it. This document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus are not an offer to sell these Notes, and these documents are not soliciting an offer to buy these Notes, in any jurisdiction where the offer or sale is not permitted. You should not, under any circumstances, assume that the information in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus is correct on any date after their respective dates.<br>**HSBC USA Inc.**<br>**$8,325,000 <br> Autocallable Yield Notes Linked to<br> the iShares<sup>®</sup> MSCI EAFE ETF**<br>**January 30, 2023**<br>**Pricing Supplement** |
| Certain ERISA and Related Considerations | S-56 | &nbsp;&nbsp;&nbsp; You should only rely on the information contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. We have not authorized anyone to provide you with information or to make any representation to you that is not contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. If anyone provides you with different or inconsistent information, you should not rely on it. This document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus are not an offer to sell these Notes, and these documents are not soliciting an offer to buy these Notes, in any jurisdiction where the offer or sale is not permitted. You should not, under any circumstances, assume that the information in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus is correct on any date after their respective dates.<br>**HSBC USA Inc.**<br>**$8,325,000 <br> Autocallable Yield Notes Linked to<br> the iShares<sup>®</sup> MSCI EAFE ETF**<br>**January 30, 2023**<br>**Pricing Supplement** |
| U.S. Federal Income Tax Considerations | S-58 | &nbsp;&nbsp;&nbsp; You should only rely on the information contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. We have not authorized anyone to provide you with information or to make any representation to you that is not contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. If anyone provides you with different or inconsistent information, you should not rely on it. This document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus are not an offer to sell these Notes, and these documents are not soliciting an offer to buy these Notes, in any jurisdiction where the offer or sale is not permitted. You should not, under any circumstances, assume that the information in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus is correct on any date after their respective dates.<br>**HSBC USA Inc.**<br>**$8,325,000 <br> Autocallable Yield Notes Linked to<br> the iShares<sup>®</sup> MSCI EAFE ETF**<br>**January 30, 2023**<br>**Pricing Supplement** |
| Supplemental Plan of Distribution (Conflicts of Interest) | S-83 | &nbsp;&nbsp;&nbsp; You should only rely on the information contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. We have not authorized anyone to provide you with information or to make any representation to you that is not contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. If anyone provides you with different or inconsistent information, you should not rely on it. This document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus are not an offer to sell these Notes, and these documents are not soliciting an offer to buy these Notes, in any jurisdiction where the offer or sale is not permitted. You should not, under any circumstances, assume that the information in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus is correct on any date after their respective dates.<br>**HSBC USA Inc.**<br>**$8,325,000 <br> Autocallable Yield Notes Linked to<br> the iShares<sup>®</sup> MSCI EAFE ETF**<br>**January 30, 2023**<br>**Pricing Supplement** |
| **Prospectus** |  | &nbsp;&nbsp;&nbsp; You should only rely on the information contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. We have not authorized anyone to provide you with information or to make any representation to you that is not contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. If anyone provides you with different or inconsistent information, you should not rely on it. This document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus are not an offer to sell these Notes, and these documents are not soliciting an offer to buy these Notes, in any jurisdiction where the offer or sale is not permitted. You should not, under any circumstances, assume that the information in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus is correct on any date after their respective dates.<br>**HSBC USA Inc.**<br>**$8,325,000 <br> Autocallable Yield Notes Linked to<br> the iShares<sup>®</sup> MSCI EAFE ETF**<br>**January 30, 2023**<br>**Pricing Supplement** |
|  |  | &nbsp;&nbsp;&nbsp; You should only rely on the information contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. We have not authorized anyone to provide you with information or to make any representation to you that is not contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. If anyone provides you with different or inconsistent information, you should not rely on it. This document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus are not an offer to sell these Notes, and these documents are not soliciting an offer to buy these Notes, in any jurisdiction where the offer or sale is not permitted. You should not, under any circumstances, assume that the information in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus is correct on any date after their respective dates.<br>**HSBC USA Inc.**<br>**$8,325,000 <br> Autocallable Yield Notes Linked to<br> the iShares<sup>®</sup> MSCI EAFE ETF**<br>**January 30, 2023**<br>**Pricing Supplement** |
| About this Prospectus | 1 | &nbsp;&nbsp;&nbsp; You should only rely on the information contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. We have not authorized anyone to provide you with information or to make any representation to you that is not contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. If anyone provides you with different or inconsistent information, you should not rely on it. This document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus are not an offer to sell these Notes, and these documents are not soliciting an offer to buy these Notes, in any jurisdiction where the offer or sale is not permitted. You should not, under any circumstances, assume that the information in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus is correct on any date after their respective dates.<br>**HSBC USA Inc.**<br>**$8,325,000 <br> Autocallable Yield Notes Linked to<br> the iShares<sup>®</sup> MSCI EAFE ETF**<br>**January 30, 2023**<br>**Pricing Supplement** |
| Risk Factors | 2 | &nbsp;&nbsp;&nbsp; You should only rely on the information contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. We have not authorized anyone to provide you with information or to make any representation to you that is not contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. If anyone provides you with different or inconsistent information, you should not rely on it. This document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus are not an offer to sell these Notes, and these documents are not soliciting an offer to buy these Notes, in any jurisdiction where the offer or sale is not permitted. You should not, under any circumstances, assume that the information in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus is correct on any date after their respective dates.<br>**HSBC USA Inc.**<br>**$8,325,000 <br> Autocallable Yield Notes Linked to<br> the iShares<sup>®</sup> MSCI EAFE ETF**<br>**January 30, 2023**<br>**Pricing Supplement** |
| Where You Can Find More Information | 3 | &nbsp;&nbsp;&nbsp; You should only rely on the information contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. We have not authorized anyone to provide you with information or to make any representation to you that is not contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. If anyone provides you with different or inconsistent information, you should not rely on it. This document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus are not an offer to sell these Notes, and these documents are not soliciting an offer to buy these Notes, in any jurisdiction where the offer or sale is not permitted. You should not, under any circumstances, assume that the information in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus is correct on any date after their respective dates.<br>**HSBC USA Inc.**<br>**$8,325,000 <br> Autocallable Yield Notes Linked to<br> the iShares<sup>®</sup> MSCI EAFE ETF**<br>**January 30, 2023**<br>**Pricing Supplement** |
| Special Note Regarding Forward-Looking Statements | 4 | &nbsp;&nbsp;&nbsp; You should only rely on the information contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. We have not authorized anyone to provide you with information or to make any representation to you that is not contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. If anyone provides you with different or inconsistent information, you should not rely on it. This document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus are not an offer to sell these Notes, and these documents are not soliciting an offer to buy these Notes, in any jurisdiction where the offer or sale is not permitted. You should not, under any circumstances, assume that the information in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus is correct on any date after their respective dates.<br>**HSBC USA Inc.**<br>**$8,325,000 <br> Autocallable Yield Notes Linked to<br> the iShares<sup>®</sup> MSCI EAFE ETF**<br>**January 30, 2023**<br>**Pricing Supplement** |
| HSBC USA Inc. | 7 | &nbsp;&nbsp;&nbsp; You should only rely on the information contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. We have not authorized anyone to provide you with information or to make any representation to you that is not contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. If anyone provides you with different or inconsistent information, you should not rely on it. This document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus are not an offer to sell these Notes, and these documents are not soliciting an offer to buy these Notes, in any jurisdiction where the offer or sale is not permitted. You should not, under any circumstances, assume that the information in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus is correct on any date after their respective dates.<br>**HSBC USA Inc.**<br>**$8,325,000 <br> Autocallable Yield Notes Linked to<br> the iShares<sup>®</sup> MSCI EAFE ETF**<br>**January 30, 2023**<br>**Pricing Supplement** |
| Use of Proceeds | 8 | &nbsp;&nbsp;&nbsp; You should only rely on the information contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. We have not authorized anyone to provide you with information or to make any representation to you that is not contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. If anyone provides you with different or inconsistent information, you should not rely on it. This document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus are not an offer to sell these Notes, and these documents are not soliciting an offer to buy these Notes, in any jurisdiction where the offer or sale is not permitted. You should not, under any circumstances, assume that the information in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus is correct on any date after their respective dates.<br>**HSBC USA Inc.**<br>**$8,325,000 <br> Autocallable Yield Notes Linked to<br> the iShares<sup>®</sup> MSCI EAFE ETF**<br>**January 30, 2023**<br>**Pricing Supplement** |
| Description of Debt Securities | 9 | &nbsp;&nbsp;&nbsp; You should only rely on the information contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. We have not authorized anyone to provide you with information or to make any representation to you that is not contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. If anyone provides you with different or inconsistent information, you should not rely on it. This document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus are not an offer to sell these Notes, and these documents are not soliciting an offer to buy these Notes, in any jurisdiction where the offer or sale is not permitted. You should not, under any circumstances, assume that the information in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus is correct on any date after their respective dates.<br>**HSBC USA Inc.**<br>**$8,325,000 <br> Autocallable Yield Notes Linked to<br> the iShares<sup>®</sup> MSCI EAFE ETF**<br>**January 30, 2023**<br>**Pricing Supplement** |
| Description of Preferred Stock | 20 | &nbsp;&nbsp;&nbsp; You should only rely on the information contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. We have not authorized anyone to provide you with information or to make any representation to you that is not contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. If anyone provides you with different or inconsistent information, you should not rely on it. This document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus are not an offer to sell these Notes, and these documents are not soliciting an offer to buy these Notes, in any jurisdiction where the offer or sale is not permitted. You should not, under any circumstances, assume that the information in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus is correct on any date after their respective dates.<br>**HSBC USA Inc.**<br>**$8,325,000 <br> Autocallable Yield Notes Linked to<br> the iShares<sup>®</sup> MSCI EAFE ETF**<br>**January 30, 2023**<br>**Pricing Supplement** |
| Description of Warrants | 25 | &nbsp;&nbsp;&nbsp; You should only rely on the information contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. We have not authorized anyone to provide you with information or to make any representation to you that is not contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. If anyone provides you with different or inconsistent information, you should not rely on it. This document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus are not an offer to sell these Notes, and these documents are not soliciting an offer to buy these Notes, in any jurisdiction where the offer or sale is not permitted. You should not, under any circumstances, assume that the information in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus is correct on any date after their respective dates.<br>**HSBC USA Inc.**<br>**$8,325,000 <br> Autocallable Yield Notes Linked to<br> the iShares<sup>®</sup> MSCI EAFE ETF**<br>**January 30, 2023**<br>**Pricing Supplement** |
| Description of Purchase Contracts | 30 | &nbsp;&nbsp;&nbsp; You should only rely on the information contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. We have not authorized anyone to provide you with information or to make any representation to you that is not contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. If anyone provides you with different or inconsistent information, you should not rely on it. This document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus are not an offer to sell these Notes, and these documents are not soliciting an offer to buy these Notes, in any jurisdiction where the offer or sale is not permitted. You should not, under any circumstances, assume that the information in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus is correct on any date after their respective dates.<br>**HSBC USA Inc.**<br>**$8,325,000 <br> Autocallable Yield Notes Linked to<br> the iShares<sup>®</sup> MSCI EAFE ETF**<br>**January 30, 2023**<br>**Pricing Supplement** |
| Description of Units | 33 | &nbsp;&nbsp;&nbsp; You should only rely on the information contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. We have not authorized anyone to provide you with information or to make any representation to you that is not contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. If anyone provides you with different or inconsistent information, you should not rely on it. This document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus are not an offer to sell these Notes, and these documents are not soliciting an offer to buy these Notes, in any jurisdiction where the offer or sale is not permitted. You should not, under any circumstances, assume that the information in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus is correct on any date after their respective dates.<br>**HSBC USA Inc.**<br>**$8,325,000 <br> Autocallable Yield Notes Linked to<br> the iShares<sup>®</sup> MSCI EAFE ETF**<br>**January 30, 2023**<br>**Pricing Supplement** |
| Book-Entry Procedures | 35 | &nbsp;&nbsp;&nbsp; You should only rely on the information contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. We have not authorized anyone to provide you with information or to make any representation to you that is not contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. If anyone provides you with different or inconsistent information, you should not rely on it. This document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus are not an offer to sell these Notes, and these documents are not soliciting an offer to buy these Notes, in any jurisdiction where the offer or sale is not permitted. You should not, under any circumstances, assume that the information in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus is correct on any date after their respective dates.<br>**HSBC USA Inc.**<br>**$8,325,000 <br> Autocallable Yield Notes Linked to<br> the iShares<sup>®</sup> MSCI EAFE ETF**<br>**January 30, 2023**<br>**Pricing Supplement** |
| Limitations on Issuances in Bearer Form | 39 | &nbsp;&nbsp;&nbsp; You should only rely on the information contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. We have not authorized anyone to provide you with information or to make any representation to you that is not contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. If anyone provides you with different or inconsistent information, you should not rely on it. This document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus are not an offer to sell these Notes, and these documents are not soliciting an offer to buy these Notes, in any jurisdiction where the offer or sale is not permitted. You should not, under any circumstances, assume that the information in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus is correct on any date after their respective dates.<br>**HSBC USA Inc.**<br>**$8,325,000 <br> Autocallable Yield Notes Linked to<br> the iShares<sup>®</sup> MSCI EAFE ETF**<br>**January 30, 2023**<br>**Pricing Supplement** |
| U.S. Federal Income Tax Considerations Relating to Debt Securities | 40 | &nbsp;&nbsp;&nbsp; You should only rely on the information contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. We have not authorized anyone to provide you with information or to make any representation to you that is not contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. If anyone provides you with different or inconsistent information, you should not rely on it. This document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus are not an offer to sell these Notes, and these documents are not soliciting an offer to buy these Notes, in any jurisdiction where the offer or sale is not permitted. You should not, under any circumstances, assume that the information in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus is correct on any date after their respective dates.<br>**HSBC USA Inc.**<br>**$8,325,000 <br> Autocallable Yield Notes Linked to<br> the iShares<sup>®</sup> MSCI EAFE ETF**<br>**January 30, 2023**<br>**Pricing Supplement** |
| Certain European Union Tax Considerations | 48 | &nbsp;&nbsp;&nbsp; You should only rely on the information contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. We have not authorized anyone to provide you with information or to make any representation to you that is not contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. If anyone provides you with different or inconsistent information, you should not rely on it. This document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus are not an offer to sell these Notes, and these documents are not soliciting an offer to buy these Notes, in any jurisdiction where the offer or sale is not permitted. You should not, under any circumstances, assume that the information in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus is correct on any date after their respective dates.<br>**HSBC USA Inc.**<br>**$8,325,000 <br> Autocallable Yield Notes Linked to<br> the iShares<sup>®</sup> MSCI EAFE ETF**<br>**January 30, 2023**<br>**Pricing Supplement** |
| Plan of Distribution (Conflicts of Interest) | 49 | &nbsp;&nbsp;&nbsp; You should only rely on the information contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. We have not authorized anyone to provide you with information or to make any representation to you that is not contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. If anyone provides you with different or inconsistent information, you should not rely on it. This document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus are not an offer to sell these Notes, and these documents are not soliciting an offer to buy these Notes, in any jurisdiction where the offer or sale is not permitted. You should not, under any circumstances, assume that the information in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus is correct on any date after their respective dates.<br>**HSBC USA Inc.**<br>**$8,325,000 <br> Autocallable Yield Notes Linked to<br> the iShares<sup>®</sup> MSCI EAFE ETF**<br>**January 30, 2023**<br>**Pricing Supplement** |
| Notice to Canadian Investors | 52 | &nbsp;&nbsp;&nbsp; You should only rely on the information contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. We have not authorized anyone to provide you with information or to make any representation to you that is not contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. If anyone provides you with different or inconsistent information, you should not rely on it. This document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus are not an offer to sell these Notes, and these documents are not soliciting an offer to buy these Notes, in any jurisdiction where the offer or sale is not permitted. You should not, under any circumstances, assume that the information in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus is correct on any date after their respective dates.<br>**HSBC USA Inc.**<br>**$8,325,000 <br> Autocallable Yield Notes Linked to<br> the iShares<sup>®</sup> MSCI EAFE ETF**<br>**January 30, 2023**<br>**Pricing Supplement** |
| Notice to EEA Investors | 53 | &nbsp;&nbsp;&nbsp; You should only rely on the information contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. We have not authorized anyone to provide you with information or to make any representation to you that is not contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. If anyone provides you with different or inconsistent information, you should not rely on it. This document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus are not an offer to sell these Notes, and these documents are not soliciting an offer to buy these Notes, in any jurisdiction where the offer or sale is not permitted. You should not, under any circumstances, assume that the information in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus is correct on any date after their respective dates.<br>**HSBC USA Inc.**<br>**$8,325,000 <br> Autocallable Yield Notes Linked to<br> the iShares<sup>®</sup> MSCI EAFE ETF**<br>**January 30, 2023**<br>**Pricing Supplement** |
| Notice to UK Investors | 54 | &nbsp;&nbsp;&nbsp; You should only rely on the information contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. We have not authorized anyone to provide you with information or to make any representation to you that is not contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. If anyone provides you with different or inconsistent information, you should not rely on it. This document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus are not an offer to sell these Notes, and these documents are not soliciting an offer to buy these Notes, in any jurisdiction where the offer or sale is not permitted. You should not, under any circumstances, assume that the information in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus is correct on any date after their respective dates.<br>**HSBC USA Inc.**<br>**$8,325,000 <br> Autocallable Yield Notes Linked to<br> the iShares<sup>®</sup> MSCI EAFE ETF**<br>**January 30, 2023**<br>**Pricing Supplement** |
| UK Financial Promotion | 54 | &nbsp;&nbsp;&nbsp; You should only rely on the information contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. We have not authorized anyone to provide you with information or to make any representation to you that is not contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. If anyone provides you with different or inconsistent information, you should not rely on it. This document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus are not an offer to sell these Notes, and these documents are not soliciting an offer to buy these Notes, in any jurisdiction where the offer or sale is not permitted. You should not, under any circumstances, assume that the information in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus is correct on any date after their respective dates.<br>**HSBC USA Inc.**<br>**$8,325,000 <br> Autocallable Yield Notes Linked to<br> the iShares<sup>®</sup> MSCI EAFE ETF**<br>**January 30, 2023**<br>**Pricing Supplement** |
| Certain ERISA and Related Matters | 55 | &nbsp;&nbsp;&nbsp; You should only rely on the information contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. We have not authorized anyone to provide you with information or to make any representation to you that is not contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. If anyone provides you with different or inconsistent information, you should not rely on it. This document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus are not an offer to sell these Notes, and these documents are not soliciting an offer to buy these Notes, in any jurisdiction where the offer or sale is not permitted. You should not, under any circumstances, assume that the information in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus is correct on any date after their respective dates.<br>**HSBC USA Inc.**<br>**$8,325,000 <br> Autocallable Yield Notes Linked to<br> the iShares<sup>®</sup> MSCI EAFE ETF**<br>**January 30, 2023**<br>**Pricing Supplement** |
| Legal Opinions | 57 | &nbsp;&nbsp;&nbsp; You should only rely on the information contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. We have not authorized anyone to provide you with information or to make any representation to you that is not contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. If anyone provides you with different or inconsistent information, you should not rely on it. This document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus are not an offer to sell these Notes, and these documents are not soliciting an offer to buy these Notes, in any jurisdiction where the offer or sale is not permitted. You should not, under any circumstances, assume that the information in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus is correct on any date after their respective dates.<br>**HSBC USA Inc.**<br>**$8,325,000 <br> Autocallable Yield Notes Linked to<br> the iShares<sup>®</sup> MSCI EAFE ETF**<br>**January 30, 2023**<br>**Pricing Supplement** |
| Experts | 58 | &nbsp;&nbsp;&nbsp; You should only rely on the information contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. We have not authorized anyone to provide you with information or to make any representation to you that is not contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. If anyone provides you with different or inconsistent information, you should not rely on it. This document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus are not an offer to sell these Notes, and these documents are not soliciting an offer to buy these Notes, in any jurisdiction where the offer or sale is not permitted. You should not, under any circumstances, assume that the information in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus is correct on any date after their respective dates.<br>**HSBC USA Inc.**<br>**$8,325,000 <br> Autocallable Yield Notes Linked to<br> the iShares<sup>®</sup> MSCI EAFE ETF**<br>**January 30, 2023**<br>**Pricing Supplement** |

---

## Ex-Filing

**EX-FILING FEES**

**Calculation of Filing Fee Table**

S-3<br> (Form Type)

**HSBC USA Inc.**<br> (Exact Name of Registrant as Specified in its Charter)

(Translation of Registrant's Name into English)

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Security Type** | **Security Class<br> Title** | **Fee Calculation<br> or Carry Forward Rule** | **Amount<br> Registered** | **Proposed Maximum<br> Offering Price Per Unit** | **Maximum<br> Aggregate<br> Offering Price** | **Fee Rate** | **Amount of <br> Registration Fee** |
| Fees to Be Paid | Debt | Debt Securities | Rule 457(r) |  |  | $8325000 | $110.20 per $1,000,000 | $917.42 |

---

### Attached PDF Documents

**Attachment 1:** `tm234869d18_424b2.pdf`

Filed Pursuant to Rule 424(b)(2)
Registration No. 333-253385
January 30, 2023
PRICING SUPPLEMENT
(To Prospectus dated February 23, 2021,
Prospectus Supplement dated February 23, 2021 and
ETF Underlying Supplement dated February 23, 2021)

HSBC USA Inc.
$8,325,000
Autocallable Yield Notes

![img-0.jpeg](img-0.jpeg)

## Linked to the iShares® MSCI EAFE ETF

- Semi-annual Coupon payments at a rate of 3.625% (equivalent to 7.25% per annum), payable on each Coupon Payment Date
- Callable semi-annually at the principal amount plus the applicable Coupon on any Call Observation Date on or after July 28, 2023 if the Official Closing Price of the Reference Asset is at or above the Call Threshold
- If the Notes are not called you will receive protection from the first 25.00% of any losses if the Reference Return is less than -25.00%, with 1.3333x exposure to each 1% decline beyond -25.00%, and in such a case, you will lose all or a portion of your principal amount
- A 1 year and 6 month term if not called
- All payments on the Notes are subject to the credit risk of HSBC USA Inc.

The Autocallable Yield Notes (each a "Note" and collectively the "Notes") offered hereunder will not be listed on any securities exchange or automated quotation system.

Neither the U.S. Securities and Exchange Commission (the "SEC") nor any state securities commission has approved or disapproved of the Notes or passed upon the accuracy or the adequacy of this document, the accompanying prospectus, prospectus supplement or ETF Underlying Supplement. Any representation to the contrary is a criminal offense.

We have appointed HSBC Securities (USA) Inc., an affiliate of ours, as the agent for the sale of the Notes. HSBC Securities (USA) Inc. will purchase the Notes from us for distribution to other registered broker-dealers or will offer the Notes directly to investors. In addition, HSBC Securities (USA) Inc. or another of its affiliates or agents may use this pricing supplement in market-making transactions in any Notes after their initial sale. Unless we or our agent inform you otherwise in the confirmation of sale, this pricing supplement is being used in a market-making transaction. See "Supplemental Plan of Distribution (Conflicts of Interest)" on page PS-14 of this document.

Investment in the Notes involves certain risks. You should refer to "Risk Factors" beginning on page PS-7 of this document, page S-1 of the accompanying prospectus supplement and page S-1 of the accompanying ETF Underlying Supplement.

The Estimated Initial Value of the Notes on the Trade Date is $993.50 per Note, which is less than the price to public. The market value of the Notes at any time will reflect many factors and cannot be predicted with accuracy. See "Estimated Initial Value" on page PS-3 and "Risk Factors" beginning on page PS-7 of this document for additional information.

|  | Price to Public | Underwriting Discount 1 | Proceeds to Issuer |
| --- | --- | --- | --- |
| Per Note | $1,000.00 | $3.75 | $996.25 |
| Total | $8,325,000.00 | $31,218.75 | $8,293,781.25 |

HSBC USA Inc. or one of our affiliates may pay varying underwriting discounts of up to 0.375% per $1,000 Principal Amount in connection with the distribution of the Notes to other registered broker-dealers. See "Supplemental Plan of Distribution (Conflicts of Interest)" on page PS-14 of this document.

The Notes:

| Are Not FDIC Insured | Are Not Bank Guaranteed | May Lose Value |
| --- | --- | --- |

HSBC

HSBC USA Inc.
Autocallable Yield Notes
HSBC

This document relates to a single offering of Autocallable Yield Notes. The Notes will have the terms described in this document and the accompanying prospectus, prospectus supplement, and ETF Underlying Supplement. If the terms of the Notes offered hereby are inconsistent with those described in the accompanying prospectus, prospectus supplement, or ETF Underlying Supplement, the terms described in this document shall control.

This document relates to an offering of Notes linked to the Reference Asset. The purchaser of a Note will acquire a senior unsecured debt security of HSBC USA Inc. linked to the Reference Asset as described below. The following key terms relate to the offering of the Notes:

Issuer: HSBC USA Inc.
Principal Amount: $1,000 per Note
Reference Asset: The iShares® MSCI EAFE ETF (Ticker: EFA)
Trade Date: January 30, 2023
Pricing Date: January 26, 2023
Original Issue Date: February 2, 2023
Final Valuation Date: July 30, 2024, subject to adjustment as described under “Additional Terms of the Notes-Valuation Dates” in the accompanying ETF Underlying Supplement.
Maturity Date: August 2, 2024. The Maturity Date is subject to adjustment as described under “Additional Terms of the Notes-Coupon Payment Dates, Call Payment Dates and Maturity Date” in the accompanying ETF Underlying Supplement.
Call Feature: If the Official Closing Price of the Reference Asset is at or above the Call Threshold on any Observation Date the Notes will be automatically called, and you will receive a cash payment, per $1,000 Principal Amount, equal to the Principal Amount plus the applicable Coupon on the corresponding Call Payment Date.
Call Threshold: 100.00% of the Initial Value
Payment at Maturity: Unless the Notes are called, on the Maturity Date, for each $1,000 Principal Amount, we will pay you the Final Settlement Value.
Final Settlement Value: Unless the Notes are called, for each $1,000 Principal Amount, you will receive a cash payment on the Maturity Date, calculated as follows:

- If the Reference Return is greater than or equal to -25.00%: $1,000 + final Coupon.
- If the Reference Return of is less than -25.00%: $1,000 + [$1,000 × (Reference Return + 25.00%) × Downside Leverage Factor] + final Coupon.

If the Notes are not called and the Final Value is less than the Buffer Value, you will receive protection from the first 25.00% of any losses, with 1.3333x exposure to each 1% decline that the Reference Return is less than -25.00%. Under these circumstances will lose up to 100% of the Principal Amount. Even with the Coupons paid over the term of the Notes, your return on the Notes may be negative.

Reference Return: The quotient, expressed as a percentage, calculated as follows:

Final Value - Initial Value
Initial Value

| Observation Dates, Call Payment Dates and Coupon Payment Dates: | Observation Dates | Coupon Payment Dates |
| --- | --- | --- |
|  | July 28, 2023 | August 2, 2023 |
|  | January 30, 2024 | February 2, 2024 |
|  | July 30, 2024 (the Final Valuation Date) | August 2, 2024 (the Maturity Date) |

PS-2

PS-3

*These Observation Dates are also Call Observation Dates
**These Coupon Payment Dates are also Call Payment Dates

Each subject to postponement as described under “Additional Terms of the Notes-Valuation Dates” and “Additional Terms of the Notes-Coupon Payment Dates, Call Payment Dates and Maturity Date” in the accompanying ETF Underlying Supplement.

Call Observation Dates: The applicable Observation Dates on or after July 28, 2023, as indicated above.

Call Payment Dates: The applicable Coupon Payment Dates on or after May 2, 2023, as indicated above.

Coupon Rate: 3.625% per semi-annual period (equivalent to 7.25% per annum)

Initial Value: $71.14, which was the Official Closing Price on the Pricing Date.

Final Value: The Official Closing Price of the Reference Asset on the Final Valuation Date.

Buffer Value: 75.00% of the Initial Value.

Downside Leverage Factor: 1/0.75 (1.3333x)

CUSIP/ISIN: 40441XF70 / US40441XF702

Form of Notes: Book-Entry

Listing: The Notes will not be listed on any securities exchange or quotation system.

Estimated Initial Value: The Estimated Initial Value of the Notes is less than the price you pay to purchase the Notes. The Estimated Initial Value does not represent a minimum price at which we or any of our affiliates would be willing to purchase your Notes in the secondary market, if any, at any time. See “Risk Factors - The Estimated Initial Value of the Notes, which was determined by us on the Trade Date, is less than the price to public and may differ from the market value of the Notes in the secondary market, if any.”

PS-4

# GENERAL

This document relates to an offering of Notes linked to the Reference Asset. The purchaser of a Note will acquire a senior unsecured debt security of HSBC USA Inc. Although the offering of Notes relates to the Reference Asset, you should not construe that fact as a recommendation as to the merits of acquiring an investment linked to the Reference Asset or any security included in the Reference Asset or as to the suitability of an investment in the Notes.

You should read this document together with the prospectus dated February 23, 2021, the prospectus supplement dated February 23, 2021 and the ETF Underlying Supplement dated February 23, 2021. If the terms of the Notes offered hereby are inconsistent with those described in the accompanying prospectus, prospectus supplement or ETF Underlying Supplement, the terms described in this document shall control. You should carefully consider, among other things, the matters set forth in "Risk Factors" beginning on page PS-7 of this document, page S-1 of the prospectus supplement and page S-1 of the ETF Underlying Supplement, as the Notes involve risks not associated with conventional debt securities. We urge you to consult your investment, legal, tax, accounting and other advisors before you invest in the Notes. As used herein, references to the "Issuer", "HSBC", "we", "us" and "our" are to HSBC USA Inc.

HSBC has filed a registration statement (including a prospectus, prospectus supplement and ETF Underlying Supplement) with the SEC for the offering to which this document relates. Before you invest, you should read the prospectus, prospectus supplement and ETF Underlying Supplement in that registration statement and other documents HSBC has filed with the SEC for more complete information about HSBC and this offering. You may get these documents for free by visiting EDGAR on the SEC's web site at www.sec.gov. Alternatively, HSBC Securities (USA) Inc. or any dealer participating in this offering will arrange to send you the prospectus, prospectus supplement and ETF Underlying Supplement if you request them by calling toll-free 1-866-811-8049.

You may also obtain:

- The ETF Underlying Supplement at: https://www.sec.gov/Archives/edgar/data/83246/000110465921026629/tm217170d6_424b2.htm
- The prospectus supplement at: https://www.sec.gov/Archives/edgar/data/83246/000110465921026609/tm217170d2_424b2.htm
- The prospectus at: https://www.sec.gov/Archives/edgar/data/83246/000110465921026585/tm217170d7_424b3.htm

PAYMENT ON THE NOTES

## Call Feature

If the Official Closing Price of the Reference Asset is at or above the Call Threshold on any Observation Date the Notes will be automatically called, and you will receive a cash payment, per $1,000 Principal Amount, equal to the Principal Amount plus the applicable Coupon on the corresponding Call Payment Date.

## Coupon

Unless the Notes are called, we will pay a semi-annual Coupon payment on each Coupon Payment Date. For information regarding the record dates applicable to the Coupons payable on the Notes, please see the section entitled “Description of Notes-Interest and Principal Payments-Recipients of Interest Payments” beginning on page S-17 in the accompanying prospectus supplement. The Coupon Rate is 7.25% per annum (or $36.25 per $1,000 Principal Amount per semi-annual period).

## Payment at Maturity

Unless the Notes are called, on the Maturity Date and for each $1,000 Principal Amount, you will receive a cash payment equal to the Final Settlement Value determined as follows:

- If the Reference Return is greater than or equal to -25.00%:
$1,000 + final Coupon

- If the Reference Return is less than -25.00%:
$1,000 + [$1,000 × (Reference Return + 25.00%) × Downside Leverage Factor] + final Coupon.

If the Notes are not called and the Final Value is less than the Buffer Value, you will receive protection from the first 25.00% of any losses, with 1.3333x exposure to each 1% decline of the Reference Return beyond -25.00%. Under these circumstances will lose up to 100% of the Principal Amount. Even with the Coupons paid over the term of the Notes, your return on the Notes may be negative.

## Calculation Agent

We or one of our affiliates will act as calculation agent with respect to the Notes.

## Reference Sponsor

The reference sponsor of the EFA is iShares, Inc.

PS-5

PS-6

# INVESTOR SUITABILITY

## The Notes may be suitable for you if:

- You believe that the Final Value will be at or above the Buffer Value.
- You seek a fixed semi-annual Coupon, that will be paid at the Coupon Rate of 7.25% per annum to be paid on each Coupon Payment Date, unless the Notes are called.
- You are willing to invest in the Notes based on the fact that your maximum potential return is limited to the Coupons payable on the Notes.
- You do not seek an investment that provides an opportunity to participate in the appreciation of the Reference Asset.
- You are willing to make an investment that is exposed to the potential downside performance of the Reference Asset if the Notes are not called on a 1.3333-to-1 basis for each percentage point that the Reference Return declines below -25.00%.
- You are willing to lose up to 100% of the Principal Amount.
- You are willing to hold the Notes which will be automatically called on any Observation Date on which the Official Closing Price of the Reference Asset is at or above the Call Threshold, or you are otherwise willing to hold the Notes to maturity.
- You are willing to forgo the dividends or other distributions paid on the stocks included in the Reference Asset.
- You do not seek an investment for which there will be an active secondary market.
- You are willing to accept the risk and return profile of the Notes versus a conventional debt security with a comparable maturity issued by HSBC or another issuer with a similar credit rating.
- You are comfortable with the creditworthiness of HSBC, as Issuer of the Notes.

## The Notes may not be suitable for you if:

- You believe that the Final Value will be below the Buffer Value.
- You believe that the Coupon will not provide you with your desired return.
- You are unwilling to invest in the Notes based on the fact that your maximum potential return is limited to the Coupons payable on the Notes.
- You seek an investment that provides an opportunity to participate in the appreciation of the Reference Asset.
- You are unwilling to make an investment that is exposed to the potential downside performance of the Reference Asset if the Notes are not called on a 1.3333-to-1 basis for each percentage point that the Reference Return declines below -25.00%.
- You seek an investment that provides full return of principal at maturity.
- You are unable or unwilling to hold Notes that will be automatically called on any Observation Date on which the Official Closing Price of the Reference Asset is at or above the Call Threshold, or you are otherwise unable or unwilling to hold the Notes to maturity.
- You prefer to receive the dividends or other distributions paid on the stocks included in the Reference Asset.
- You seek an investment for which there will be an active secondary market.
- You prefer the lower risk, and therefore accept the potentially lower returns, of conventional debt securities with comparable maturities issued by HSBC or another issuer with a similar credit rating.
- You are not willing or are unable to assume the credit risk associated with HSBC, as Issuer of the Notes.

PS-7

# RISK FACTORS

We urge you to read the section "Risk Factors" beginning on page S-1 of the accompanying prospectus supplement and page S-1 of the accompanying ETF Underlying Supplement. You should understand the risks of investing in the Notes and should reach an investment decision only after careful consideration, with your advisors, of the suitability of the Notes in light of your particular financial circumstances and the information set forth in this document and the accompanying prospectus, prospectus supplement and ETF Underlying Supplement. In addition to the risks discussed below, you should review "Risk Factors" in the accompanying prospectus supplement and ETF Underlying Supplement including the explanation of risks relating to the Notes described in the following sections:

- “-Risks Relating to All Note Issuances” in the prospectus supplement;
- “-General Risks Related to Indices” in the ETF Underlying Supplement;
- “-Securities Prices Generally Are Subject to Political, Economic, Financial, and Social Factors that Apply to the Markets in which They Trade and, to a Lesser Extent, Foreign Markets” in the ETF Underlying Supplement; and
- “- Time Differences Between the Domestic and Foreign Markets and New York City May Create Discrepancies in the Trading Level or Price of the Notes” in the ETF Underlying Supplement.

You will be subject to significant risks not associated with conventional fixed-rate or floating-rate debt securities.

## Risks Relating to the Structure or Features of the Notes

The Notes do not guarantee any return of principal and you may lose all of your Principal Amount.

The Notes do not guarantee any return of principal. The Notes differ from ordinary debt securities in that we will not pay you 100% of the Principal Amount of your Notes if the Notes are not called and the Final Value is less than the Buffer Value. In this case, the Payment at Maturity you will be entitled to receive will be less than the Principal Amount and you will lose 1.3333% for each 1% that the Reference Return is less than -25.00%. You may lose up to 100% of your investment at maturity. Even with the Coupons received prior to or at maturity, your return on the Notes may be negative in this case.

## The Notes may be called prior to the Maturity Date.

If the Notes are called early, the holding period over which you may receive coupon payments could be as little as approximately 6 months. There is no guarantee that you would be able to reinvest the proceeds from an investment in the Notes at a comparable return for a similar level of risk in the event the Notes are called prior to the Maturity Date.

## Your return on the Notes is limited to the Principal Amount plus the Coupons, regardless of any appreciation in the value of the Reference Asset.

For each $1,000 Principal Amount, you will receive $1,000 at maturity plus the final Coupon, regardless of any appreciation in the value of the Reference Asset, which may be significant. Accordingly, the return on the Notes may be significantly less than the return on a direct investment in the stocks included in the Reference Asset during the term of the Notes.

## Higher Coupon Rates or lower Buffer Values are generally associated with Reference Assets with greater expected volatility and therefore can indicate a greater risk of loss.

"Volatility" refers to the frequency and magnitude of changes in the value of the Reference Asset. The greater the expected volatility with respect to the Reference Asset on the Trade Date, the higher the expectation as of the Trade Date that the value of the Reference Asset could close below the Buffer Value on the Final Valuation Date, indicating a higher expected risk of non-payment of Coupons or loss on the Notes. This greater expected risk will generally be reflected in a higher Coupon Rate than the yield payable on our conventional debt securities with a similar maturity, or in more favorable terms (such as a lower Buffer Value or a higher Coupon Rate) than for similar securities linked to the performance of the Reference Asset with a lower expected volatility as of the Trade Date. You should therefore understand that a relatively higher Coupon Rate may indicate an increased risk of loss. Further, a relatively lower Buffer Value may not necessarily indicate that the Notes have a greater likelihood of a repayment of principal at maturity. The volatility of the Reference Asset can change significantly over the term of the Notes. The value of the Reference Asset for your Notes could fall sharply, which could result in a significant loss of principal. You should be willing to accept the downside market risk of the Reference Asset and the potential to lose some or all of your principal at maturity.

## The amount payable on the Notes is not linked to the values of the Reference Asset at any time other than the Final Valuation Date.

The payments on the Notes will be based on the Official Closing Prices of the Reference Asset on the Final Valuation Date, subject to postponement certain Market Disruption Events. If the Notes are not called, even if the value of the Reference Asset is greater than or equal to the Buffer Value during the term of the Notes other than on the Final Valuation Date but then decreases on the Final Valuation Date to a value that is less than the Buffer Value, the Payment at Maturity will be less, possibly significantly less, than it would have been had the Payment at Maturity been linked to the value of the Reference Asset prior to such decrease.

## Risks Relating to the Reference Asset

Changes that affect the Reference Asset may affect the value of the Reference Asset and the market value of the Notes and the amount you will receive on the Notes and the amount you will receive at maturity.

The policies of the reference sponsor of the Reference Asset, concerning additions, deletions and substitutions of the stocks included in the Reference Asset and the manner in which the reference sponsor takes account of certain changes affecting those stocks may affect the value of the Reference Asset. The policies of the reference sponsor could also affect the value of the Reference Asset. The reference sponsor may discontinue or suspend calculation or dissemination of the Reference Asset. Any such actions could affect the value of the Reference Asset and the value of and the return on the Notes.

Risks associated with non-U.S. companies.

The value of the EFA depends upon the stocks of non-U.S. companies, and thus involves risks associated with the home countries of those non-U.S. companies. The prices of these non-U.S. stocks may be affected by political, economic, financial and social factors in the home country of each applicable company, including changes in that country's government, economic and fiscal policies, currency exchange laws or other laws or restrictions, which could affect the value of the Notes. These foreign securities may have less liquidity and could be more volatile than many of the securities traded in U.S. or other securities markets. Direct or indirect government intervention to stabilize the relevant foreign securities markets, as well as cross shareholdings in foreign companies, may affect trading levels or prices and volumes in those markets. The other special risks associated with foreign securities may include, but are not limited to: less liquidity and smaller market capitalizations; less rigorous regulation of securities markets; different accounting and disclosure standards; governmental interference; currency fluctuations; higher inflation; and social, economic and political uncertainties. These factors may adversely affect the performance of the EFA and, as a result, the value of the Notes.

The Notes will not be adjusted for changes in exchange rates.

Although the equity securities that are held by the EFA are traded in currencies other than U.S. dollars, and your Notes are denominated in U.S. dollars, the amount payable on your Notes at maturity, if any, will not be adjusted for changes in the exchange rates between the U.S. dollar and the currencies in which these non-U.S. equity securities are denominated. Changes in exchange rates, however, may also reflect changes in the applicable non-U.S. economies that in turn may affect the value of the EFA and therefore the relevant Notes. The amount we pay in respect of your Notes on the maturity date, if any, will be determined solely in accordance with the procedures described in this document.

General Risk Factors

The Notes are subject to the credit risk of HSBC USA Inc.

The Notes are senior unsecured debt obligations of the Issuer, HSBC, and are not, either directly or indirectly, an obligation of any third party. As further described in the accompanying prospectus supplement and prospectus, the Notes will rank on par with all of the other unsecured and unsubordinated debt obligations of HSBC, except such obligations as may be preferred by operation of law. Any payment to be made on the Notes, including any return of principal at maturity, depends on the ability of HSBC to satisfy its obligations as they come due. As a result, the actual and perceived creditworthiness of HSBC may affect the market value of the Notes and, in the event HSBC were to default on its obligations, you may not receive the amounts owed to you under the terms of the Notes.

The Notes are not insured or guaranteed by any governmental agency of the United States or any other jurisdiction.

The Notes are not deposit liabilities or other obligations of a bank and are not insured or guaranteed by the Federal Deposit Insurance Corporation or any other governmental agency or program of the United States or any other jurisdiction. An investment in the Notes is subject to the credit risk of HSBC, and in the event that HSBC is unable to pay its obligations as they become due, you may not receive the full payments due on the Notes.

The Estimated Initial Value of the Notes, which was determined by us on the Trade Date, is less than the price to public and may differ from the market value of the Notes in the secondary market, if any.

The Estimated Initial Value of the Notes was calculated by us on the Trade Date and is less than the price to public. The Estimated Initial Value reflects our and our affiliates' internal funding rate, which is the borrowing rate paid to issue market-linked securities, as well as the mid-market value of the embedded derivatives in the Notes. This internal funding rate is typically lower than the rate we would use when we issue conventional fixed or floating rate debt securities. As a result of the difference between our internal funding rate and the rate we would use when we issue conventional fixed or floating rate debt securities, the Estimated Initial Value of the Notes may be lower if it were based on the prices at which our fixed or floating rate debt securities trade in the secondary market. In addition, if we were to use the rate we use for our conventional fixed or floating rate debt issuances, we would expect the economic terms of the Notes to be more favorable to you. We determined the value of the embedded derivatives in the Notes by reference to our or our affiliates' internal pricing models. These pricing models consider certain assumptions and variables, which can include volatility and interest rates. Different pricing models and assumptions could provide valuations for the Notes that are different from our Estimated Initial Value. These pricing models rely in part on certain forecasts about future events, which may prove to be incorrect. The Estimated Initial Value does not represent a minimum price at which we or any of our affiliates would be willing to purchase your Notes in the secondary market (if any exists) at any time.

The price of your Notes in the secondary market, if any, immediately after the Trade Date is expected to be less than the price to public.

The price to public takes into account certain costs. These costs, which will be used or retained by us or one of our affiliates, include the underwriting discount, our affiliates' projected hedging profits (which may or may not be realized) for assuming risks inherent in hedging

PS-8

our obligations under the Notes, and the costs associated with structuring and hedging our obligations under the Notes. If you were to sell your Notes in the secondary market, if any, the price you would receive for your Notes may be less than the price you paid for them because secondary market prices will not take into account these costs. The price of your Notes in the secondary market, if any, at any time after issuance will vary based on many factors, including the value of the Reference Asset and changes in market conditions, and cannot be predicted with accuracy. The Notes are not designed to be short-term trading instruments, and you should, therefore, be able and willing to hold the Notes to maturity. Any sale of the Notes prior to maturity could result in a loss to you.

**If we were to repurchase your Notes immediately after the Original Issue Date, the price you receive may be higher than the Estimated Initial Value of the Notes.**

Assuming that all relevant factors remain constant after the Original Issue Date, the price at which HSBC Securities (USA) Inc. may initially buy or sell the Notes in the secondary market, if any, and the value that may initially be used for customer account statements, if any, may exceed the Estimated Initial Value on the Trade Date for a temporary period expected to be approximately 3 months after the Original Issue Date. This temporary price difference may exist because, in our discretion, we may elect to effectively reimburse to investors a portion of the estimated cost of hedging our obligations under the Notes and other costs in connection with the Notes that we will no longer expect to incur over the term of the Notes. We will make such discretionary election and determine this temporary reimbursement period on the basis of a number of factors, including the tenor of the Notes and any agreement we may have with the distributors of the Notes. The amount of our estimated costs which we effectively reimburse to investors in this way may not be allocated ratably throughout the reimbursement period, and we may discontinue such reimbursement at any time or revise the duration of the reimbursement period after the Original Issue Date of the Notes based on changes in market conditions and other factors that cannot be predicted.

**You will not have any ownership interest in the stocks included in the Reference Asset.**

As a holder of the Notes, you will not have any ownership interest in the stocks included in the Reference Asset, such as rights to vote, dividend payments or other distributions. Because the return on the Notes will not reflect any dividends on those stocks, the Notes may underperform an investment in the stocks included in the Reference Asset.

**The Notes lack liquidity.**

The Notes will not be listed on any securities exchange or automated quotation system. HSBC Securities (USA) Inc. is not required to offer to purchase the Notes in the secondary market, if any exists. Even if there is a secondary market, it may not provide enough liquidity to allow you to trade or sell the Notes easily. Because other dealers are not likely to make a secondary market for the Notes, the price at which you may be able to trade your Notes is likely to depend on the price, if any, at which HSBC Securities (USA) Inc. is willing to buy the Notes.

**Potential conflicts of interest may exist.**

An affiliate of HSBC has a minority equity interest in the owner of an electronic platform, through which we may make available certain structured investments offering materials. HSBC and its affiliates play a variety of roles in connection with the issuance of the Notes, including acting as calculation agent and hedging our obligations under the Notes. In performing these duties, the economic interests of the calculation agent and other affiliates of ours are potentially adverse to your interests as an investor in the Notes. We will not have any obligation to consider your interests as a holder of the Notes in taking any action that might affect the value of your Notes.

**Uncertain tax treatment.**

For a discussion of the U.S. federal income tax consequences of your investment in a Note, please see the discussion under "U.S. Federal Income Tax Considerations" herein and the discussion under "U.S. Federal Income Tax Considerations" in the accompanying prospectus supplement.

PS-9

# ILLUSTRATIVE EXAMPLES

The following table and examples are provided for illustrative purposes only and are hypothetical. They do not purport to be representative of every possible scenario concerning increases or decreases in the value of the Reference Asset relative to the Initial Value. We cannot predict the Official Closing Price of the Reference Asset on any Observation Date, including the Final Valuation Date. The assumptions we have made in connection with the illustrations set forth below may not reflect actual events. You should not take this illustration or these examples as an indication or assurance of the expected performance of the Reference Asset or the return on the Notes.

The table and examples below illustrate how the Coupon and the Payment at Maturity would be calculated with respect to a $1,000 investment in the Notes, given a range of hypothetical performances of the Reference Asset. The hypothetical returns on the Notes below are numbers, expressed as percentages, that result from comparing the Payment at Maturity per $1,000 Principal Amount to $1,000. You should consider carefully whether the Notes are suitable to your investment goals. The numbers appearing in the following table and examples have been rounded for ease of analysis. The following table and examples assume the following:

| Principal Amount: | $1,000 |
| --- | --- |
| Hypothetical Initial Value: | 1,000.00* |
| Hypothetical Call Threshold: | 1,000.00 (100.00% of the Initial Value) |
| Hypothetical Buffer Value: | 750.00 (75.00% of the Initial Value) |
| Downside Leverage Factor: | 1/0.75 (1.3333x) |
| Hypothetical Coupon Rate: | 7.25% per annum (3.625% for each semi-annual period in which it is payable). If the Notes are not called, the Coupons paid over the term of the Notes would total $108.75 per $1,000 Principal Amount. |

* The hypothetical Initial Value of 1,000.00 used in the examples below has been chosen for illustrative purposes only and does not represent the actual Initial Value of the Reference Asset. The actual Initial Value of the Reference Asset was determined on the Pricing Date and is set forth on PS-3 of this pricing supplement.

## Summary of the Examples

|  | Notes Are Called on an Observation Date | Notes Are Not Called on Any Observation Dates |  |
| --- | --- | --- | --- |
|  | Example 1 | Example 2 | Example 3 |
| Initial Value | 1,000.00 | 1,000.00 | 1,000.00 |
| Call Threshold | 1,000.00 | 1,000.00 | 1,000.00 |
| Buffer Value | 750.00 | 750.00 | 750.00 |
| Official Closing Price / Percentage Change on the: |  |  |  |
| First Observation Date | 787.50 / -21.25% | 810.00 / -19.00% | 810.00 / -19.00% |
| Second Observation Date | 1,200.00 / 20.00% | 787.50 / -21.25% | 600.00 / -40.00% |
| Final Valuation Date | N/A | 780.00 / -22.00% | 400.00 / -60.00% |
| Coupon Payment Amounts Prior to Maturity or Call | 1 x $36.25 = $36.25 | 2 x $36.25 = $72.50 | 2 x $36.25 = $72.50 |
| Payment if Notes are Called | $1,036.25 | N/A | N/A |
| Payment at Maturity | N/A | $1,036.25 | $1,000 + [$1,000 x (-60.00% +25.00%) x 1.3333] + $36.25 = $569.58 |
| Return of the Notes | 7.25% | 10.875% | -35.792% |

Example 1-The Official Closing Price of the Reference Asset on the second Observation Date is greater than or equal to the Call Threshold.

| Initial Value |  | Official Closing Price |
| --- | --- | --- |
| 1,000.00 |  | 1,250.00 (125.00% of Initial Value) |

| Payment Upon a Call: | $1,036.25 |
| --- | --- |

Because the Official Closing Price of the Reference Asset on the second Observation Date is at or above the Call Threshold, the Notes will be called and you will receive $1,036.25 per Note, reflecting the Principal Amount plus the Coupon. When added to the Coupon payments of $36.25 received in respect of the previous Coupon Payment Dates, we will have paid you a total of $1,072.50 per Note, resulting in a 7.25% return on the Notes. No extra payment will be made on account of the Reference Asset closing above the Initial Value.

Example 2- The Notes are not called and the Final Value is greater than or equal to the Buffer Value.

| Initial Value |  | Final Value |
| --- | --- | --- |
| 1,000.00 |  | 780.00 (78.00% of Initial Value) |

| Reference Return: | -22.00% |
| --- | --- |
| Payment at Maturity: | $1,036.25 |

Because the Final Value is greater than or equal to the Buffer Value, you will receive $1,036.25 per Note, reflecting the Principal Amount plus the final Coupon.

When added to the Coupon payments of $72.50 received prior to maturity, we will have paid you a total of $1,108.75 per Note, resulting in a 10.875% return on the Notes.

Example 3-The Notes are not called and the Final Value is less than the Buffer Value.

| Initial Value |  | Final Value |
| --- | --- | --- |
| 1,000.00 |  | 400.00 (40.00% of Initial Value) |

| Reference Return: | -60.00% |
| --- | --- |
| Payment at Maturity: | $569.58 |

Because the Final Value is less than the Buffer Value, you will receive $569.58 per $1,000 Principal Amount, calculated as follows:

Final Settlement Value = $1,000 + [$1,000 × (Reference Return + 25.00%)]
× Downside Leverage Factor] + final Coupon.

$$
\$1,000 + [\$1,000 \times (-60.00\% + 25.00\%) \times 1.3333] + \$36.25 = \$569.58
$$

When added to the Coupon payments of $72.50 received prior to maturity, we will pay you a total of $642.08, resulting in a -35.792% return on the Notes.

If the Notes are not called and the Final Value is less than the Buffer Value, you will be exposed to any decrease in the value of the Reference Asset on a 1.25:1 basis and could lose up to 100% of your principal at maturity.

PS-12

PS-13

# DESCRIPTION OF THE REFERENCE ASSET

## Description of the EFA

The EFA seeks investment results that correspond generally to the price and yield performance, before fees and expenses, of publicly traded securities in the European, Australasian, and Far Eastern markets, as measured by the MSCI EAFE® Index. The shares of the EFA are listed and trade on the NYSE Arca under the symbol "EFA."

For more information about the Reference Asset, see “The iShares® MSCI EAFE ETF” beginning on page S-35 of the accompanying ETF Underlying Supplement.

## Historical Performance of the EFA

The following graph sets forth the historical performance of the EFA based on the daily historical closing values from January 30, 2013 through January 30, 2023. We obtained the closing values below from the Bloomberg Professional® service. We have not undertaken any independent review of, or made any due diligence inquiry with respect to, the information obtained from the Bloomberg Professional® service.

![img-0.jpeg](img-0.jpeg)

The historical values of the EFA should not be taken as an indication of future performance, and no assurance can be given as to the Official Closing Price of the EFA on any Observation Date, including the Final Valuation Date.

PS-14

# EVENTS OF DEFAULT AND ACCELERATION

If the Notes have become immediately due and payable following an Event of Default (as defined in the accompanying prospectus) with respect to the Notes, the calculation agent will determine the accelerated payment due and payable in the same general manner as described in this document except that in such a case, the scheduled trading day immediately preceding the date of acceleration will be used as the Final Valuation Date for purposes of determining the Reference Return of the Reference Asset, and the accelerated Maturity Date will be three business days after the accelerated Final Valuation Date. If a Market Disruption Event exists with respect to the Reference Asset on that scheduled trading day, then the accelerated Final Valuation Date for the Reference Asset will be postponed for up to five scheduled trading days (in the same manner used for postponing the originally scheduled Final Valuation Date). The accelerated Maturity Date will also be postponed by an equal number of business days following the postponed accelerated Final Valuation Date. If the Notes have become immediately due and payable following an Event of Default, you will not be entitled to any additional payments with respect to the Notes. For more information, see "Description of Debt Securities - Senior Debt Securities - Events of Default" in the accompanying prospectus.

# SUPPLEMENTAL PLAN OF DISTRIBUTION (CONFLICTS OF INTEREST)

We have appointed HSBC Securities (USA) Inc., an affiliate of HSBC, as the agent for the sale of the Notes. Pursuant to the terms of a distribution agreement, HSBC Securities (USA) Inc. will purchase the Notes from HSBC at the price to public less the underwriting discount set forth on the cover page of this pricing supplement, for distribution to other registered broker-dealers or will offer the Notes directly to investors. HSBC Securities (USA) Inc. has offered the Notes at the price to public set forth on the cover page of this document. HSBC USA Inc. or one of our affiliates may pay varying underwriting discounts of up to 0.375% per $1,000 Principal Amount in connection with the distribution of the Notes to other registered broker-dealers.

An affiliate of HSBC has paid or may pay in the future an amount to broker-dealers in connection with the costs of the continuing implementation of systems to support the Notes.

In addition, HSBC Securities (USA) Inc. or another of its affiliates or agents may use this pricing supplement in market-making transactions after the initial sale of the Notes, but is under no obligation to make a market in the Notes and may discontinue any market-making activities at any time without notice.

See "Supplemental Plan of Distribution (Conflicts of Interest)" on page S-83 in the prospectus supplement

Delivery of the Notes will be made against payment for the Notes on the Original Issue Date set forth on the inside cover page of this document, which is more than two business days following the Trade Date. Under Rule 15c6-1 under the Securities Exchange Act of 1934, trades in the secondary market generally are required to settle in two business days, unless the parties to that trade expressly agree otherwise. Accordingly, purchasers who wish to trade the Notes more than two business days prior to the Original Issue Date will be required to specify an alternate settlement cycle at the time of any such trade to prevent a failed settlement, and should consult their own advisors.

# U.S. FEDERAL INCOME TAX CONSIDERATIONS

There is no direct legal authority as to the proper tax treatment of the Notes, and therefore significant aspects of the tax treatment of the Notes are uncertain as to both the timing and character of any inclusion in income in respect of the Notes. Under one approach, each Note should be treated as a put option written by you (the "Put Option") that permits us to "cash settle" the Put Option, and a deposit with us of cash in an amount equal to the Principal Amount of the Note (the "Deposit") to secure your potential obligation under the Put Option, as described in the accompanying prospectus supplement under the heading "U.S. Federal Income Tax Considerations - Tax Treatment of U.S. Holders - Certain Notes Treated as a Put Option and a Deposit or an Executory Contract - Certain Notes Treated as a Put Option and a Deposit." We intend to treat the Notes consistent with this approach, and we intend to treat the Deposits as non-contingent debt instruments for U.S. federal income tax purposes. Pursuant to the terms of the Notes, you agree to treat each Note as consisting of the Deposit and the Put Option for all U.S. federal income tax purposes. Subject to the limitations described therein, and based on certain factual representations received from us, in the opinion of our special U.S. tax counsel, Mayer Brown LLP, it is reasonable to treat a Note as consisting of the Deposit and the Put Option for all U.S. federal income tax purposes. Because there are no statutory provisions, regulations, published rulings or judicial decisions addressing the characterization for U.S. federal income tax purposes of securities with terms that are substantially the same as those of the Notes, other characterizations and treatments are possible and the timing and character of income in respect of the Notes might differ from the treatment described above. We do not plan to request a ruling from the Internal Revenue Service (the "IRS") regarding the tax treatment of the Notes, and the IRS or a court may not agree with the tax treatment described herein.

We will not attempt to ascertain whether the Reference Asset or any of the entities whose stock is included in the Reference Asset would be treated as a passive foreign investment company ("PFIC") or United States real property holding corporation ("USRPHC"), both as

defined for U.S. federal income tax purposes. If the Reference Asset or one or more of the entities whose stock is included in the Reference Asset were so treated, certain adverse U.S. federal income tax consequences might apply. You should refer to information filed with the SEC and other authorities by the Reference Asset and the entities whose stock is included in the Reference Asset and consult your tax advisor regarding the possible consequences to you if the Reference Asset or one or more of the entities whose stock is included in the Reference Asset is or becomes a PFIC or a USRPHC.

U.S. Holders. Please see the discussion under the heading "U.S. Federal Income Tax Considerations - Tax Treatment of U.S. Holders - Certain Notes Treated as a Put Option and a Deposit or an Executory Contract - Certain Notes Treated as a Put Option and a Deposit" in the accompanying prospectus supplement for further discussion of U.S. federal income tax considerations applicable to U.S. holders (as defined in the accompanying prospectus supplement). For purposes of dividing the annual coupon rate of 7.25% on the Notes among interest on the Deposit and Put Premium, 5.40% constitutes interest on the Deposit and 1.85% constitutes Put Premium.

If the Notes are redeemed prior to maturity, you should recognize the total Put Premium received as short-term capital gain at that time.

Non-U.S. Holders. Please see the discussion under the heading "U.S. Federal Income Tax Considerations - Tax Treatment of Non-U.S. Holders" in the accompanying prospectus supplement for further discussion of U.S. federal income tax considerations applicable to non-U.S. holders (as defined in the accompanying prospectus supplement). Because the U.S. federal income tax treatment (including the applicability of withholding) of the coupon payments on the Notes is uncertain, the entire amount of the coupon payments will be subject to U.S. federal income tax withholding at a 30% rate (or at a lower rate under an applicable income tax treaty). We will not pay any additional amounts in respect of such withholding.

Under current law, while the matter is not entirely clear, individual non-U.S. holders, and entities whose property is potentially includible in those individuals' gross estates for U.S. federal estate tax purposes (for example, a trust funded by such an individual and with respect to which the individual has retained certain interests or powers), should note that, absent an applicable treaty benefit, the Notes are likely to be treated as U.S. situs property, subject to U.S. federal estate tax. These individuals and entities should consult their own tax advisors regarding the U.S. federal estate tax consequences of investing in the Notes.

A "dividend equivalent" payment is treated as a dividend from sources within the United States and such payments generally would be subject to a 30% U.S. withholding tax if paid to a non-U.S. holder. Under U.S. Treasury Department regulations, payments (including deemed payments) with respect to equity-linked instruments ("ELIs") that are "specified ELIs" may be treated as dividend equivalents if such specified ELIs reference an interest in an "underlying security," which is generally any interest in an entity taxable as a corporation for U.S. federal income tax purposes if a payment with respect to such interest could give rise to a U.S. source dividend. However, Internal Revenue Service guidance provides that withholding on dividend equivalent payments will not apply to specified ELIs that are not delta-one instruments and that are issued before January 1, 2025. Based on the Issuer's determination that the Notes are not "delta-one" instruments, non-U.S. holders should not be subject to withholding on dividend equivalent payments, if any, under the Notes. However, it is possible that the Notes could be treated as deemed reissued for U.S. federal income tax purposes upon the occurrence of certain events affecting the Reference Asset or the Notes, and following such occurrence the Notes could be treated as subject to withholding on dividend equivalent payments. Non-U.S. holders that enter, or have entered, into other transactions in respect of the Reference Asset or the Notes should consult their tax advisors as to the application of the dividend equivalent withholding tax in the context of the Notes and their other transactions. If any payments are treated as dividend equivalents subject to withholding, we (or the applicable paying agent) would be entitled to withhold taxes without being required to pay any additional amounts with respect to amounts so withheld.

For a discussion of the U.S. federal income tax consequences of your investment in a Note, please see the discussion under "U.S. Federal Income Tax Considerations" in the accompanying prospectus supplement.

PROSPECTIVE PURCHASERS OF NOTES SHOULD CONSULT THEIR TAX ADVISORS AS TO THE FEDERAL, STATE, LOCAL, AND OTHER TAX CONSEQUENCES TO THEM OF THE PURCHASE, OWNERSHIP AND DISPOSITION OF NOTES.

## VALIDITY OF THE NOTES

In the opinion of Mayer Brown LLP, as counsel to the Issuer, when this pricing supplement has been attached to, and duly notated on, the master note that represents the Notes pursuant to the Senior Indenture referred to in the prospectus supplement dated February 23, 2021, and issued and paid for as contemplated herein, the Notes offered by this pricing supplement will be valid, binding and enforceable obligations of the Issuer, entitled to the benefits of the Senior Indenture, subject to applicable bankruptcy, insolvency and similar laws affecting creditors' rights generally, concepts of reasonableness and equitable principles of general applicability (including, without limitation, concepts of good faith, fair dealing and the lack of bad faith). This opinion is given as of the date hereof and is limited to the laws of the State of New York, the Maryland General Corporation Law (including the statutory provisions, all applicable provisions of the Maryland Constitution and the reported judicial decisions interpreting the foregoing) and the federal laws of the United States of America. This opinion is subject to customary assumptions about the trustee's authorization, execution and delivery of the Senior Indenture and the genuineness of signatures and to such counsel's reliance on the Issuer and other sources as to certain factual matters,

PS-15

PS-16

all as stated in the legal opinion dated February 23, 2021, which has been filed as Exhibit 5.3 to the Issuer's registration statement on Form S-3 dated February 23, 2021.

TABLE OF CONTENTS

Pricing Supplement

General PS-4
Payment on the Notes PS-5
Investor Suitability PS-6
Risk Factors PS-7
Illustrative Examples PS-10
Description of the Reference Asset PS-13
Events of Default and Acceleration PS-14
Supplemental Plan of Distribution (Conflicts of Interest) PS-14
U.S. Federal Income Tax Considerations PS-14
Validity of the Notes PS-15

ETF Underlying Supplement

Risk Factors S-1
Reference Sponsors and Index Funds S-12
The Consumer Staples Select Sector SPDR® Fund S-13
The Energy Select Sector SPDR® Fund S-15
The Financial Select Sector SPDR® Fund S-17
The Health Care Select Sector SPDR® Fund S-19
The Technology Select Sector SPDR® Fund S-21
The Utilities Select Sector SPDR® Fund S-23
The iShares® China Large-Cap ETF S-25
The iShares® Global Clean Energy ETF S-28
The iShares® Latin America 40 ETF S-31
The iShares® MSCI Brazil ETF S-33
The iShares® MSCI EAFE ETF S-35
The iShares® MSCI Emerging Markets ETF S-40
The iShares® MSCI Mexico ETF S-41
The iShares® Russell 2000 ETF S-44
The iShares® Transportation Average ETF S-47
The iShares® U.S. Real Estate ETF S-49
The Invesco QQQ TrustTM, Series I S-51
The SPDR® Dow Jones® Industrial Average ETF Trust S-54
The SPDR® S&amp;P 500® ETF Trust S-56
The SPDR® S&amp;P® Bank ETF S-62
The SPDR® S&amp;P® Regional Banking ETF S-65
The SPDR® S&amp;P Midcap 400® ETF Trust S-66
The SPDR® S&amp;P® Biotech ETF S-73
The SPDR® S&amp;P® Oil &amp; Gas Exploration &amp; Production ETF S-74
The VanEck® Vectors Gold Miners ETF S-75
The Vanguard® FTSE Emerging Markets ETF S-78
The WisdomTree® Japan Hedged Equity Fund S-80
Additional Terms of the Notes S-84

Prospectus Supplement

Risk Factors S-1
Pricing Supplement S-12
Description of Notes S-14
Use of Proceeds and Hedging S-55
Certain ERISA and Related Considerations S-56
U.S. Federal Income Tax Considerations S-58
Supplemental Plan of Distribution (Conflicts of Interest) S-83

Prospectus

About this Prospectus 1
Risk Factors 2
Where You Can Find More Information 3
Special Note Regarding Forward-Looking Statements 4
HSBC USA Inc. 7
Use of Proceeds 8
Description of Debt Securities 9
Description of Preferred Stock 20
Description of Warrants 25
Description of Purchase Contracts 30
Description of Units 33
Book-Entry Procedures 35
Limitations on Issuances in Bearer Form 39
U.S. Federal Income Tax Considerations Relating to Debt Securities 40
Certain European Union Tax Considerations 48
Plan of Distribution (Conflicts of Interest) 49
Notice to Canadian Investors 52
Notice to EEA Investors 53
Notice to UK Investors 54
UK Financial Promotion 54
Certain ERISA and Related Matters 55
Legal Opinions 57
Experts 58

You should only rely on the information contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. We have not authorized anyone to provide you with information or to make any representation to you that is not contained in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus. If anyone provides you with different or inconsistent information, you should not rely on it. This document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus are not an offer to sell these Notes, and these documents are not soliciting an offer to buy these Notes, in any jurisdiction where the offer or sale is not permitted. You should not, under any circumstances, assume that the information in this document, the accompanying ETF Underlying Supplement, prospectus supplement and prospectus is correct on any date after their respective dates.

HSBC USA Inc.

$8,325,000
Autocallable Yield Notes Linked to the iShares® MSCI EAFE ETF

January 30, 2023

Pricing Supplement